Cosmetic or pharmaceutical use of avenanthramide l

Avenanthramide L or oat extract containing avenanthramide L addresses the need for effective skin treatments by inhibiting the neurokinin-1 receptor, enhancing skin barrier function, and reducing itching through its anti-inflammatory and antioxidant effects.

JP2024160251AInactive Publication Date: 2024-11-13SYMRISE GMBH & CO KG
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024119516
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for new drugs or preparations that are effective in preventing and treating skin conditions associated with itching and skin barrier dysfunction, while being non-toxic, well-tolerated, stable, odorless, and cost-effective.

Method used

The use of avenanthramide L or oat extract containing avenanthramide L, which acts as a neurokinin-1 receptor antagonist, anti-inflammatory, and antioxidant, to prevent and treat skin diseases and conditions, including those with barrier-related, inflammatory, immunoallergic, atherogenic, or hyperproliferative components.

Benefits of technology

Avenanthramide L effectively inhibits the neurokinin-1 receptor, upregulates small heat shock proteins and CD44 expression, and exhibits strong antioxidant properties, providing significant relief from itching and improving skin barrier function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160251000001_ABST
    Figure 2024160251000001_ABST
Patent Text Reader

Abstract

To provide new agents or preparations for use in skin protection and in the prevention and / or treatment of dermatoses, in particular itch and / or itch-related dermatoses.SOLUTION: The present invention relates to: the cosmetic or pharmaceutical use of avenanthramide L or an oat extract comprising avenanthramide L; avenanthramide L or an oat extract comprising avenanthramide L as a neurokinin-1 receptor NK1R antagonist; and a method for preparing avenalumic acid and / or avenanthramide L.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention generally relates to avenanthramide L or an oat extract containing avenanthramide L. Use of the compound as a cosmetic or pharmaceutical agent; Neurokinin-1 receptor (NK1R) antagonist Avenanthramide L or oat extract containing avenanthramide L as a stimulant; and methods for preparing avenalumic acid and / or avenanthramide L. . [Background technology]

[0002] Oatmeal has been shown to act as a soothing agent to relieve the itching and irritation associated with various dry skin conditions. It has been used for centuries. Medical texts recommend oatmeal as a treatment for a variety of skin conditions. Promoting topical application of colloidal oatmeal in dermatological practice The most common clinical application is the treatment of pruritic skin conditions, such as atopic dermatitis and allergies. Its clinical application is as an adjunctive therapy for sensitive or irritant contact dermatitis. The indirect anti-irritant activity of oats has been established both in vitro and in clinical studies. The extract inhibited the ionophore-stimulated release of arachidonic acid from phospholipids in keratinocytes. It has been shown to reduce skin separation and inhibit prostaglandin biosynthesis. Despite its widespread use, the phytonutrients present in oats that mediate anti-inflammatory activity are unknown. There are few studies that have examined the chemical composition.

[0003] Oats are made up of two main species, Avena sativa L. and Avena n. uda L. (synonym Avena sativa by Gillet and Magne) subsp. nuda (L.), and Avena sativa by Koern A. sativa is found in oats (including oats var. nuda (L.)). Also known as oat (abalone oat) or hulled oat, it is grown in cool temperate climates, especially in northern Europe. It is cultivated mainly in the cool, moist regions of North America and Canada. A. nuda is a plant with a high yield. When harvested, the husk is removed and it has a husk-free threshing property similar to that of wheat, making it a popular choice for wheat. Also known as oats or dehulled oats. Hulled oats are a global Represents the majority of oat production, although naked oats are the most common. This excludes China, which is a large variety of

[0004] The composition of oats is mainly starch (65-85%), protein (15-20%), enzymes Approximately 2-8.5% of the diet contains fats (3-11%) and a high content of β-glucan. Oats also contain other important bioactive compounds, e.g., phenolic compounds. Contains:

[0005] Phenolic compounds have antioxidant properties and inhibit the production of reactive oxygen species (i.e. superoxide). Degenerative diseases involving anions, hydroxyl radicals and peroxy radicals (e.g., heart disease and It can protect against diseases such as cancer.

[0006] The general definition of a phenolic compound is a benzene ring containing one or more hydroxyl groups. Any compound containing a zene ring. Phenolic acids, flavonoids, condensed tannins Examples are coumarins and alkylresorcinols. In cereals, these compounds are predominant It is located within the pericarp and can be concentrated by peeling the kernel to produce the bran. Phenolic compounds are flavonoids (flavonols, flavones, isoflavones, anthosides, etc.) They are classified into cyanines, flavanols, flavanones, etc.) and non-flavonoids. Phenolic compounds can be either in the free phenol or glycoside form. Phenolic compounds tend to be relatively polar and are usually present in pure or or aqueous alcohols, e.g., ethanol and methanol, or aqueous acetone. Many phenolic compounds in cereals (e.g., phenolic acids and flavonoids) ) have also been reported in fruits and plants, although some phenols are confined to one plant species, e.g. For example, it is typical of oat avenanthramide.

[0007] Phenolic compounds have been shown to possess many activities, most importantly , preventing lipid peroxidation and cellular oxidative damage mediated by harmful free radicals Antioxidant activity. This property scavenges free radicals and removes hydrogen atoms or electrons, or or the ability of phenolic compounds to donate chelated metal cations [Dyk es et al., Cereal Foods World, 2007, pp. 105-111].

[0008] The types and concentrations of phenolic compounds in whole wheat grains depend on the plant diversity and properties of the grain. High levels of phenolic acids, tocopherols and alkyl (alkenyl) In addition to containing resorcinol derivatives, oats contain avenanthramides ( Avns; N-cinnamoyl anthranilate alkaloids or anthranilic acid amides Also known as corn syrup), which are not found in any other cereal grain.

[0009] Avenanthramides (hereafter referred to as Avns or a single avenanthramide compound) Avn is a compound that is a mixture of anthranilic acid and hydroxycinnamic acid with an amide bond. It is a low molecular weight phenolic amide containing an acid moiety, and is found in both A. sativa and A. nud a is also a group of naturally occurring phenolic amides in oats. First identified as a phytoalexin produced by plants in response to exposure to pathogens .

[0010] Oats contain a unique group of approximately 40 different types of Avns, which It is present in both grains and leaves. The most abundant is Avn A (N-(4'-hydroxycinnamate) 5-hydroxyanthranilic acid), Avn B (N-(4'-hydroxy-3 '-Methoxycinnamoyl)-5-hydroxyanthranilic acid) and Avn C (N- (3'-4'-dihydroxycinnamoyl)-5-hydroxyanthranilic acid), These are the amides of 5-hydroxyanthranilic acid, p-coumarin, ferulic acid and These Avns are constitutively expressed in seeds and nuts. They appear in almost all milled fractions, but their highest concentrations are in the bran and seeds. It occurs in the outer layer of the fruit [Boz H., Czech Journal of Food Sciences, 2015, Vol. 33(No. 5): pp. 399-404. The total content of avenanthramides (Avns) in rice varies from about 2 to 100 mg / kg depending on the variety and agronomic treatment. 700 mg / kg (0.0002-0.07%) [Maliaro va M. et al., Journal of the Brazilian Chemical Society, 2015, Volume 26(No. 11), Pages 2369-2378].

[0011] Avns showed strong antioxidant activity both in vitro and in vivo, and in cells The development of oxidative dysfunction and oxidative stress-related diseases, e.g., neurodegenerative and cardiovascular diseases It has anti-inflammatory, anti-irritant, anti-atherogenic and anti-proliferative activities that can prevent or limit the growth of and provide additional protection against skin irritation, aging, CHD and cancer. The study of Perrelli A. et al., Oxidative Medicine and Cellular Longevity, 2018, DOI:10.1155 / 2018 / 6015351].

[0012] The extraction of Avns from oats can be performed using various solvent compositions, e.g., pure or diluted Ethanol and methanol were used. The extraction procedure is carried out using, for example, naked oat, 50% aqueous ethanol, etc. under high heat. [Tong L et al., Journal of Integrative Agr iculture, 2014, vol. 13, p. 1809].

[0013] Maliarova, M. et al., Journal of the Brazilian Chemical Society, 2015, Vol. 26(11), 2369-2378 Page, Methanol, Ethanol, and the Extraction of Avns from Naked Oat Bran The efficiency of isopropanol and ethanol was compared. The optimum conditions for the highest yield of Avns were The extraction temperature was 55°C and the extraction time was 165 min.

[0014] The antioxidant activity of Avns was similar to that of typical cereal constituents, ferulic acid, gentisic acid, and p-hyaluronic acid. Hydroxybenzoic acid, protocatechuic acid, It was found to have antioxidant activity 10 to 30 times higher than that of valinic acid, vanillic acid, and vanillin. The Avns differ in antioxidant activity, with Avn C having the highest activity, followed by Avn B and This is followed by Avn A. Avn-rich oat extracts showed in vitro L Inhibits LDL oxidation. Oat antioxidants lower serum cholesterol and LDL cholesterol. Potential to reduce cardiovascular risk by inhibiting teratogenic and peroxidative damage The effects of oats and oats have been confirmed in both animal studies and human clinical trials. Bran consumption not only contributes to the high fiber content, but also to the colonic Another study showed that Avns-rich enzymes could reduce the risk of cancer. Tapir extract inhibits atherosclerosis and activation of NF-kB transcription factor It has been shown that NF-kB transcription factors are regulators of infection and inflammation [Huesey in Boz, Phenolic Amides (Avenanthramides) in Oats-A Review, Czech J.Food Sci., Volume 33, 2 015(No. 5), pp. 399-404].

[0015] Despite its widespread use in the treatment of skin irritation, the anti-inflammatory Phytochemicals Responsible for Antiinflammatory, Antipruritic, Antiirritant, Antiatherogenic and Antiproliferative Activities The substance has not yet been revealed.

[0016] WO2004 / 047833 discloses a method for inhibiting substance P-induced release of histamine from mast cells. And Equation 2: [ka] (wherein m=0, 1, 2 or 3; p=0, 1 or 2; n=0, 1 or 2, However, when n=1 or 2, p+m>0, R when n=1 or 2 1 and R 2 represents H for each pair. or together with another chemical bond (e.g., in cinnamic acid derivatives, etc.), When m=1, 2, or 3, each X independently represents OH, Oalkyl, or Oacyl. Represents, When p=1 or 2, each Y independently represents OH, Oalkyl, or Oacyl. , If p+m>0, then at least one of X and Y is selected from the group consisting of OH and O acyl. provided that the compound is selected from the group consisting of R 3 is -H or alkyl (especially -CH3 or other alkyl groups having 2 to 30 carbon atoms). In this context, R 3 The corresponding pharmacologic approved (-H for acceptable salts) The article describes the treatment and prevention of itch with the following substances:

[0017] WO2017 / 159964 describes avenin for preventing or treating hearing loss. The paper describes avenanthramides, including avenanthramide L.

[0018] EP157420 is a compound having the structure avenanthramide L as a 5-lipoxygenase inhibitor. The present application describes avenanthramides, which contain compounds which are essentially related to the above-mentioned compounds.

[0019] Lotts T. et al., Experimental Dermatology 2017 , Vol. 26(8): pp. 739-742, Dihydroavenanthramide D (CAS 69 7235-49-7, INCI name: Hydroxyphenylpropamidobenzoic acid; Symri How does SymCalmin®, the active ingredient provided by SymCalmin.com, help treat obesity? We described how IL-1 inhibits cellular degranulation through its interaction with the neurokinin-1 receptor. However, the activity of avenanthramide, especially avenanthramide L, Gender not stated.

[0020] Staender, S. et al., Targeting the Neurokinin R eceptor1 with Aprepitant:A Novel Antipru ritic Strategy, PLOS ONE (Public Library o f Science), 2010, Vol. 5(No. 6): 0010968, NKR1A Targeting neuropeptide SP by applying the antagonist aprepitant describes how this is an effective approach to treating chronic pruritus. .

[0021] Chronic pruritus is a frequent and generalized manifestation of systemic, cutaneous, neurological and psychiatric disorders. Its pathophysiology remains incompletely understood. It is currently estimated that 20-27% of the population suffers from chronic pruritus. Symptoms can range from severe to severe. It is usually characterized by its severity and duration, and by self-inflicted damage to the skin through scratching, It has a significant impact on the quality of life of patients. For a long time, pruritus has not been considered as important as pain. Given this, little attention has been paid in the past to the neurobiological basis of this condition. A second reason for the lack of exploration of specific treatment strategies is that treatment of the underlying disease may be The assumption is that the symptoms of pruritus will be automatically alleviated. The mainstays to date remain antihistamines, topical and systemic corticosteroids. or certain antidepressants. However, these have limited efficacy and Systemic application of steroids and antidepressants can also be associated with severe side effects.

[0022] Pruritus is also a common symptom of many skin diseases in which the skin barrier function is impaired, such as atopic dermatitis. The skin barrier is an important feature of AD and psoriasis. It prevents the entry of bacteria and infectious microorganisms and prevents moisture loss. Loss of barrier function can result in redness, flaking, and , characterized by cracks and rough texture ("from the outside in"), leading to dry, itchy skin Not only is it harmful to the skin, but inflammation of the epidermis can also weaken the barrier ("inside-out"). ). The underlying skin conditions associated with dry skin (xerosis) and itching can vary among patient populations. Structural and physiological changes in the skin barrier occur with age, resulting in impaired barrier function among older adults. Xerosis may result in an increased incidence of skin barrier-related abnormalities in this population. It is the most common cause of pruritus, reported in 69% of elderly patients with chronic pruritus. However, one of the most common causes of pruritus in children and adults is AD, a chronic inflammatory disorder. It is a disorder in which the patient experiences intense itching (G. Yosipovitch et al. , Acta Derm.Venereol.2019, doi:10.2340 / 000 15555-3296).

[0023] In addition, the use of toiletries, such as soaps and shampoos, which contain surfactants , which may cause adverse effects such as skin irritation, dryness, and itching. Dry skin, rough skin Skin conditions, including sensitive skin, are on the rise due to changes in living conditions and lifestyles. Many people with skin conditions experience skin irritation while cleaning their skin with detergents and / or Or after washing, the patient complains of itching, which is caused by histamine released from epidermal keratinocytes. It was shown that the β-amino acid is linked to β-amino acid (Y. Inami et al., Yakugaku Zassh i, 2012, vol. 132, pp. 1225-30).

[0024] Itch leads to scratching behavior, which exacerbates the breakdown of the skin barrier.

[0025] Therefore, in the cosmetics and pharmaceutical industry, in skin care or skin protection, and for the prevention and / or treatment of skin diseases, particularly pruritus and / or pruritus-related skin diseases. There is a continuing need for the development of new agents or preparations for use.

[0026] The substances used in the final formulation are generally available in the concentration ranges relevant for activity and administration. hand, - must be toxicologically acceptable; - must be well tolerated by the skin, - it must be stable (especially in conventional formulations), - must preferably be odorless, and - It must be cheap to produce (i.e. using standard processes and / or (starting from standard precursors) Please keep this in mind. Summary of the Invention [Problem to be solved by the invention]

[0027] The object of the present invention is therefore to provide a method for the treatment of skin diseases, in particular itching and / or The present invention relates to the use of such active substances or preparations in the prevention and / or treatment of skin diseases associated with pruritus. The present invention provides a method for the preparation of a pharmaceutical composition comprising the steps of:

[0028] Surprisingly, avenanthramide L or an oat extract containing avenanthramide L: Extremely interesting biological benefits, e.g., antioxidant, anti-inflammatory, anti-itch, anti-irritant and anti exhibits atherogenic activity and is therefore useful for skin care and skin protection, as well as for the treatment of skin diseases These have subsequently proven to be beneficial agents in the prevention and / or treatment of In addition, avenanthramide L or oat extracts containing avenanthramide L have been shown to be effective in treating skin diseases, especially Barrier-related, inflammatory, immunoallergic, atherogenic, dry or hyper Useful in the prevention and / or treatment of skin or keratinopathy having a proliferative component. In particular, avenanthramide L or avenanthramide-1 was found to be an effective drug. Preparations containing Nanthramide L are useful for the prevention and treatment of itch and / or itch-related skin diseases. and / or have turned out to be effective agents in the treatment of [Means for solving the problem]

[0029] Thus, the primary goal of the present invention is to develop a method for the antagonism of the neurokinin-1 receptor NK1R. Use of avenanthramide L or an oat extract containing avenanthramide L as a stimulant The purpose of this study is to provide a service that

[0030] In a second aspect, the present invention provides a method for the treatment of a CD4+-induced small heat shock protein (SHP) expression. Avenanthramide L or an enzyme containing avenanthramide L to induce expression of 44 Concerning the use of tapir extract.

[0031] In a third aspect, the present invention provides a method for the treatment of cancer, comprising administering to a patient a therapeutically effective amount of a cancer cell line comprising administering to the ... Use of avenanthramide L or an oat extract containing avenanthramide L for the development of Regarding use.

[0032] In a fourth aspect, the present invention relates to a composition for skin care, scalp care, hair care or nail care. As a cosmetic for and / or skin conditions, intolerant and sensitive skin, skin irritation , skin redness, wheals, pruritus (itching), skin aging, wrinkle formation, loss of skin volume, skin elasticity Prevention of loss of strength, pigmentation spots, pigmentation disorders, dry skin, i.e. dry skin that requires skin hydration and / or for use in the treatment of avenanthramide L or avenanthramide The present invention relates to the use of an oat extract containing L.

[0033] In a fifth aspect, the present invention relates to a method for use as a medicament, in particular for treating skin or keratinopathy. , especially barrier-related, inflammatory, immunoallergic, atherogenic, dry or is a skin disease having a hyperproliferative component, particularly a skin disease associated with pruritus and / or pruritus. Avenanthramide L or avenant for use in the prevention and / or treatment of It relates to an oat extract containing ramido L.

[0034] In a sixth aspect, the present invention provides a food, dietary supplement, cosmetic, pharmaceutical or veterinary preparation. of avenanthramide L or an oat extract containing avenanthramide L for preparing Regarding use.

[0035] In a seventh aspect, the present invention provides a compound as a neurokinin-1 receptor NK1R antagonist. The present invention relates to avenanthramide L or an oat extract containing avenanthramide L.

[0036] Finally, the present invention relates to a method for preparing avenalumic acid or avenanthramide L. Regarding.

[0037] The present invention is set forth in the appended claims. The preferred embodiments, further objects and advantages thereof are also set forth in the following detailed description taken in conjunction with the accompanying examples. This becomes clear from the detailed description. [Brief description of the drawings]

[0038] [Figure 1] 1H NMR spectrum of methyl (2E)-4-(diethylphosphoryl-)but-2-enoate, CDCl3, 300 MHz; E isomer (coupling constant = 15 Hz).

[0039] [Diagram 2] Avenalmic acid methyl ester, CDCl3, 300 MHz; 1H NMR spectrum of compound 5.

[0040] [Diagram 3] 1H NMR spectrum of avenalmic acid, DMSO-d6, 400MHz.

[0041] [Figure 4] 13C NMR spectrum of avenalmic acid, DMSO-d6, 101MHz 13C.

[0042] [Diagram 5] LCMS spectrum of avenalmic acid.

[0043] [Figure 6] 1H NMR spectrum of avenanthramide L, DMSO-d6, 400MHz.

[0044] [Figure 7] This is the 13C NMR spectrum of avenanthramide L, DMSO-d6, 101 MHz.

[0045] [Figure 8] LCMS spectrum of avenanthramide L. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0046] Within the context of the present invention, the general term "avenanthramide (anthranilic acid amide)" means , which is found mainly on oats (Avena sativa), but also on the eggs of the cabbage white butterfly (P ieris brassicae and P. rapae) and fungus-infected carnations Phenolic compounds also present in Dianthus caryophyllus It is thought to mean a member of the class of alkaloids.

[0047] Avenanthramides are found naturally and can be isolated and purified from oats. The two main species of oat are Avena sativa L. and Avena nudum. a L. (synonym: Avena sativa s by Gillet and Magne) ubsp.nuda (L.) and Avena sativa var. nuda (L.), which are found in the peripheral regions, husks, trichomes or straw. More than 50 distinct avenanthramides appear to be present in the It has been isolated from oat kernels [Collins, Journal of Agric Ultra and Food Chemistry, Vol. 37 (1989), 60~ [page 66]

[0048] Avns can be represented by the following general formula 1: [ka]

[0049] Table 1 below lists naturally occurring, isolated and / or synthetic Avns based on general formula 1. An example of this is shown.

[0050] [Table 1]

[0051] The most abundant avenanthramide in oat is avenanthramide A (2p, AF- 1 or Bp), avenanthramide B (2f, also known as AF-2 or Bf) avenanthramide C (also called 2c, AF-6 or Bc), avenanthramide Avenanthramide L (non-Collins abbreviation; CAS number 172549-38-1) (Avenanthramide O ( Collins abbreviation or 2pd), avenanthramide P (also known as 2fd) ) and avenanthramide Q (also known as 2cd).

[0052] Several studies have demonstrated that these latter avenanthramides have anti-inflammatory, antioxidant, antipruritic, and anti-inflammatory properties. Although it has been demonstrated that it has stimulatory and anti-atherogenic activity, the underlying mechanisms The mechanism and the molecules targeted remain unclear.

[0053] Naturally occurring avenanthramide compounds can alternatively be produced by organic synthesis. Cut.

[0054] The synthetic avenanthramide substances prepared above were similar to the corresponding naturally occurring avenanthramides extracted from oats. It is identical to the avenanthramide compound.

[0055] General formula 2: [ka] (wherein m=0, 1, 2 or 3; p=0, 1 or 2; n=0, 1 or 2, However, when n=1 or 2, p+m>0, R when n=1 or 2 1 and R 2 represents H for each pair. or together with another chemical bond (e.g., in cinnamic acid derivatives, etc.), When m=1, 2, or 3, each X independently represents OH, Oalkyl, or Oacyl. Represents, When p=1 or 2, each Y independently represents OH, Oalkyl, or Oacyl. , If p+m>0, then at least one of X and Y is selected from the group consisting of OH and O acyl. provided that the compound is selected from the group consisting of R 3 is -H or alkyl (especially -CH3 or other alkyl groups having 2 to 30 carbon atoms). In this context, R 3 The corresponding pharmacologic approved (also -H for acceptable salts) Non-naturally occurring avenanthramide analogs with important biological properties, such as , WO2004 / 047833A1 or WO2007 / 062957A1 It is artificially produced by organic synthesis methods.

[0056] Particularly preferred compounds of formula 2 according to the invention are n=1 or 2 and p+m>0, and / or p+m>0, and at least one of X or Y, X and Y is OH and O-al. The compound is selected from the group consisting of:

[0057] Particularly preferably, n=1 and p+m>2, provided that at least one of X and Y Formula 2, with the proviso that at least two are selected together from the group including OH and Oalkyl. The compound is used.

[0058] n=1 and m=1, 2 or 3, with the proviso that at least one X is OH and Oalkyl; and / or P=1 or 2 with the proviso that at least one Y is selected from the group consisting of OH and Oalkyl. It is also preferred to use a compound of formula 2,

[0059] If n has the value 1, then R 1 and R 2 are each preferably H, with the proviso that R 1 and R 2 It is also possible that the groups can join together to form other chemical bonds.

[0060] Formula 2 and WO2004 / 047833A1 or WO2007 / 062957A1 With respect to the definition of the specific avenanthramide compounds disclosed, the corresponding disclosures in the above documents are The disclosure is incorporated herein by reference.

[0061] The avenanthramide analog compound of formula 2 is preferably [ka] [ka] [ka] [ka] is selected from the group consisting of:

[0062] The above examples essentially relate to compounds of formula 2 where n=1.

[0063] However, the use of compounds of formula 2 where n=0 is also often preferred, in which case m+ p=0 or m+p>1 or 2, provided that among the substituents X and Y, are selected from the group consisting of OH and Oalkyl. is preferred.

[0064] [ka] [ka] [ka] It is particularly preferred to use compounds of formula 2 (n=0) selected from the group comprising:

[0065] From the above avenanthramide analogues, compound number 8 (dihydroavenanthramide D ) and number 27 are particularly preferred.

[0066] In addition to the naturally occurring avenanthramides and non-naturally occurring avenanthramide analogs described above, , N-(4'-hydroxycinnamoyl)-3-hydroxyanthranilic acid (YAvn I) and N-(3'-4'-dihydroxycinnamoyl)-3-hydroxyanthranilic Novel avenanthramide analogues, including avenanthramide acid (YAvn II), are produced in recombinant yeast. These encode the main proteins involved in the biosynthesis of phenolic esters. Two plant genes (4cl-2 from tobacco and hc from artichoke) Engineering Saccharomyces cerevisiae strains using Notably, YAvn I and YAvn II were generated by They share structural similarities with Avn A and Avn C, respectively.

[0067] Avenanthramide L or avenanthramide L represented by the general formula 1 and specified in Table 1 above Naturally occurring analogues of avenanthramide compounds other than avenanthramide L, e.g., avenanthramide A, B, C, G, H, K, etc., or non-naturally occurring groups represented by the above general formula 2 and used according to the present invention. The analog avenanthramide compounds of the present invention (hereinafter referred to as "analogs" or "analogs") The compounds known as avenanthramides (commonly known as 'avenanthramide compounds') have not been well studied or documented. Not listed. De Bruijn et al., Food Chemistry 2019, 2 Volume 77, pages 682-690, describes these typical LC-MS profiles in oat seeds. Some were identified by fragmentation patterns.

[0068] Within the context of the present invention, the term "avenanthramide L" refers to itself, CAS number 17 2549-38-1, represented by the general formula 1 and defined in Table 1, avenanthramide L (non-Collins abbreviation) avenanthramide O (Collins abbreviation) or 2pd It means "to be called."

[0069] Avenanthramide L and naturally occurring analogues of avenanthramide other than avenanthramide L The compounds represented by the general formula 1 and identified in Table 1 above (hereinafter referred to as naturally occurring compounds) Analogs of avenanthramide compounds are found in nature and are derived from oats. The two main species of oat are Avena sati va L. and Avena nuda L. (synonyms Gillet and Ma Avena sativa subsp. nuda (L.) by gne, and Koe rn, including Avena sativa var. nuda (L.). A.sat Iva is also known as common oat or hulled oat. A. nuda is similar to naked oat or oat because the husk is removed at the time the crop is collected. Also known as dehulled oats. Oats are processed to produce a composition that contains oat kernels. The avenanthramides can be separated into material fractions, with the avenanthramides being isolated from the peripheral regions, shells, trichomes or The highest concentrations appear to be in the straw.

[0070] In another version, avenanthramide L and the naturally occurring avenanthramide compounds , infected with pathogens or treated with elicitors, especially Puccinia corona Avena sativa L. inoculated with ta f.sp. avenae or isolated from Avena nuda L.

[0071] Avenanthramide L and its naturally occurring analogue avenanthramide isolated from natural sources. Alternatively, the compounds can be produced by organic synthesis. Methods for synthesizing the same are described, for example, in U.S. Pat. No. 6,096,770 and U.S. Pat. No. 6,127,399. 2, JP 60019754 A and Hungarian Patent No. HU200996B. As shown.

[0072] The synthetic avenanthramide substances prepared above were similar to the corresponding naturally occurring avenanthramides extracted from oats. It is identical to the avenanthramide compound.

[0073] Naturally occurring avenanthramide L and the naturally occurring analogue avenan isolated from oat. Apart from the sulamide compounds, non-naturally occurring analogues of the general formula 2 and as defined above are also contemplated. Avenanthramide compounds (hereinafter referred to as non-naturally occurring analogues of avenanthramides) The compounds (named compounds) can be synthesized by organic synthesis using steps known in the literature, e.g. For example, see WO2004 / 047833A1 or WO2007 / 062957A1. The avenanthramide L compound and and the corresponding disclosures regarding these analogues are incorporated herein by reference.

[0074] The term "avenanthramide L" or "analog avenanthramide compound" refers to These various isomers, especially natural isomers induced by photoisomerization upon exposure to light, The occurring trans- as well as cis-isomers are also intended to be included.

[0075] In a preferred variant of the invention, natural avenans enriched, isolated and purified from oats are Suramide L is used according to the present invention.

[0076] Avenanthramide L or naturally occurring avenanthramide compounds other than avenanthramide L The product is prepared by extraction from plants of the genus Avena, in particular any oat species, fresh or dried. or parts thereof, for example, oat species Avena sativa or Avena Crushed kernels, uncrushed kernels, husks, trichomes or oat straw of nuda It is obtained and isolated from

[0077] In a preferred variant, the starting material for the oat extract is Avena sativa Seeds or ground or unground kernels or eggs of the Avena nuda species It is nbaku straw.

[0078] Avenanthramide L or other than avenanthramide L The extraction solvent (extractant) for the advantageous extraction of naturally occurring avenanthramide compounds is water and The organic solvent is preferably selected from the group consisting of food or cosmetic products. or a solvent suitable for pharmaceutical preparations. Needless to say, such solvents are also suitable for food, cosmetic, and Or it must be suitable and suitable for the preparation of a pharmaceutical preparation.

[0079] In a more preferred variant, the extraction solvent comprises a mixture of water and alcohol or acetone. The alcohol is preferably methanol, ethanol, n-propanol, isopropanol. , n-butanol, isobutanol, t-butanol and mixtures thereof, i.e. The most preferred extraction solvents for the extraction step of the present invention are selected from the group consisting of The extractant is methanol, ethanol, n-propanol, isopropanol or acetone. tonnes, or any mixture of said solvents, each in admixture with water. The use of pure organic solvents is not favored by the simultaneous extraction of triglycerides.

[0080] The ratio of water to organic solvent in the extraction solvent, preferably the ratio of water to alcohol, The mixture ratio of acetone to water or the mixture ratio of acetone to water was determined based on the extraction solvent produced. , in the range of 10:90 to 90:10 (v / v), preferably 20:80 to 80:20 (v / v), and most preferably in the range of 30:70 to 70:30 (v / v). do.

[0081] Particularly preferred extraction solvents (extractants) are methanol / water (3:7), methanol / water (1 :1), methanol / water (7:3), ethanol / water (3:7), ethanol / water (1: 1), ethanol / water (1:4), ethanol / water (7:3), isopropanol / water ( 3:7), isopropanol / water (1:1), isopropanol / water (7:3), acetonitrile The mixtures used were acetone / water (3:7), acetone / water (1:1), and acetone / water (7:3).

[0082] From the extraction mixture (extractant), methanol / water (1:1), methanol / water (7:3 ), ethanol / water (1:1), ethanol / water (1:4), isopropanol / water (3 :7), isopropanol / water (1:1), isopropanol / water (7:3), acetone / water (3:7), acetone / water (1:1) and acetone / water (7:3) are particularly advantageous. This is because the extraction with these extractants results in high avenanthramide L content (see Table 10). These extractants result in an extract with Avena The yield of uranamide L is >150 ppm, more preferably >190 ppm, and most preferably More preferably, it is >200 ppm.

[0083] To improve the extraction yield, the oat source is heated at 30 to 80°C, preferably 40 to 70°C. More preferably, the extract is made at a temperature in the range of 50 to 60°C. The extraction yield increases with increasing temperature between 40 and 70°C. Extraction from the plant was performed at temperatures between 50 and 60°C, with the results being in terms of yield and avenanthramide L content. This produces the best results in terms of the amount of oxygen consumed and is therefore preferred.

[0084] Instead of a single natural or synthetic avenanthramide L compound, An oat extract containing oat extract may also be used according to the present invention. The term "oat extract" includes a compound or mixture of compounds obtained from oats. It is generally intended that

[0085] Avenanthramide L or a mixture of avenanthramide L and the above-described This includes naturally occurring analogues of avenanthramide compounds other than avenanthramide L such as Such extracts may be extracted with water, alcohol, acetone or a mixture thereof. for example by maceration, percolation, extraction using a Soxhlet, microwave or ultrasound) or by subcritical fluid extraction using these solvents or mixtures thereof. These are preferably in various solvent compositions, e.g., pure methanol, ethanol, n-propanol, propanol, isopropanol, n-butanol, isobutanol, t-butanol and Extracted using said solvents in mixtures, i.e. combinations thereof, or in mixtures with water. For different times at room temperature or under controlled heating, e.g., naked oat, 5 The extraction procedure was accomplished using 0% aqueous ethanol or the like [Tong L. et al., Jour nal of Integrative Agriculture, 2014, Vol. 13, [p. 1809]. Maliarova, M. et al., Journal of the Br Azilian Chemical Society, 2015, Vol. 26(11), 2 Pages 369-2378 are about the extraction of Avns from naked oat bran. The efficiency of alcohol, ethanol and isopropanol was compared. The highest yield of Avns The optimal conditions for this were methanol concentration of 70%, extraction temperature of 55°C, and extraction time of 165 min. It is.

[0086] The extract may be any plant of the genus Avena, in particular any oat species, fresh or dried, or The parts of the oat, such as Avena sativa or Avena nudum from crushed kernels, uncrushed kernels, husks, trichomes or oat straw of a. The starting product for the extraction is oat kernel residue obtained from oat oil production. It is also possible.

[0087] In a preferred variant, the starting material for the oat extract is Avena sativa Seeds or crushed or uncrushed kernels or entrails of the Avena nuda species It's a hilarious story.

[0088] Beneficially extract avenanthramide L and naturally occurring analogue avenanthramide compounds The extraction solvent (extractant) for the extraction is selected from the group consisting of a mixture of water and an organic solvent, is preferably a suitable solvent for foodstuffs or cosmetic or pharmaceutical preparations. Such solvents are not suitable or compatible for the preparation of food, cosmetic or pharmaceutical preparations. It should not be.

[0089] In a more preferred variant, the extraction solvent comprises a mixture of water and alcohol or acetone. The alcohol is preferably methanol, ethanol, n-propanol, isopropanol. , n-butanol, isobutanol, t-butanol and mixtures thereof, i.e. The most preferred extraction solvents for the extraction step of the present invention are selected from the group consisting of The extractant is methanol, ethanol, n-propanol, isopropanol or acetone. tonnes, or any mixture of said solvents, each in admixture with water. The use of pure organic solvents is not favored by the simultaneous extraction of triglycerides.

[0090] In the extraction solvent, water, organic solvent, preferably water, alcohol or water The mixing ratio of acetone to the resulting extraction solvent was 10:90 to 90: The ratio is in the range of 20:80 to 80:20 (v / v). and most preferably in the range of 30:70 to 70:30 (v / v).

[0091] Particularly preferred extraction solvents (extractants) are methanol / water (3:7), methanol / water (1 :1), methanol / water (7:3), ethanol / water (3:7), ethanol / water (1: 1), ethanol / water (1:4), ethanol / water (7:3), isopropanol / water ( 3:7), isopropanol / water (1:1), isopropanol / water (7:3), acetonitrile The mixtures used were acetone / water (3:7), acetone / water (1:1), and acetone / water (7:3).

[0092] From the extraction mixture (extractant), methanol / water (1:1), methanol / water (7:3 ), ethanol / water (1:1), ethanol / water (1:4), isopropanol / water (3 :7), isopropanol / water (1:1), isopropanol / water (7:3), acetone / water (3:7), acetone / water (1:1) and acetone / water (7:3) are particularly advantageous. This is because the extraction with these extractants resulted in high avenanthramide L content (see Table 10). These extractants result in extracts with The yield of venanthramide L is >150 ppm, more preferably >190 ppm. , most preferably >200 ppm.

[0093] To improve the extraction yield, the oat source is heated at 30 to 80°C, preferably 40 to 70°C. and more preferably at a temperature in the range of 50-60°C. The extraction yield for the grains increases with increasing temperature between 40 and 70°C. Extraction from oats at temperatures between 50 and 60°C improved yield and avenanthramide content. , which gave the best results, especially in terms of avenanthramide L content, and was therefore preferred. It is nice.

[0094] Altering the composition of the solvent can affect the avenanthramide material to be extracted, and thus the composition. It is possible to change the extraction selectivity of a compound, thereby enhancing or decreasing its biological activity. Cut.

[0095] In a preferred variant of the invention, the oat extract contains at least avenanthramide L. or at least aventhramide L and the above-mentioned and one or more of its analogues avenanthramides as defined above. nthramide compounds.

[0096] In another preferred variant of the invention, avenanthramide The oat extract containing avenanthramide L or avenanthramide L is as described and defined above. avenanthramide L and avenanthramides represented by general formula 1 or specified in Table 1. One, two, three or more selected from the group consisting of nitramides, They can further be used in combination with naturally occurring analog avenanthramide compounds. Therefore, the resulting mixture of avenanthramides was avenanthramide L, as identified in Table 1 above. and one or more analogues of avenanthramide L as defined above. Any possible combination with a mido compound may be included.

[0097] In another preferred variant of the invention, avenanthramide L or avenanthramide L-containing The oat extract containing the active ingredient avenanthramide L and as described and defined above. avenanthramide represented by the above general formula 2 or in combination with even more non-naturally occurring analog avenanthramide compounds. Thus, the mixture of avenanthramides produced can be further used as avenanthramides. avenanthramide L and one or more compounds other than avenanthramide L as represented by the above general formula 2. The compounds may include any possible combination of a number of analog avenanthramide compounds.

[0098] Preferably, avenanthramide L or , obtained from oats, is used according to the invention. Oat extract containing avenanthramide L therefore contains avenanthramides A, B, C, G At least one further analog avenge selected from the group consisting of H, K and R. It is further contemplated that avenanthrene may be used in combination with a ramid. Any combination of oat extract containing A, B, C, or avenanthramide L is One, two, three or more selected from the group consisting of G, H, K and R Many other naturally occurring analogs of avenanthramide compounds are included in combination.

[0099] In a preferred variant, avenanthramide L or oat extract containing avenanthramide L is The formulation may contain the following combinations of avenanthramides: Avns L and A; Av ns L and B;Avns L and C;Avns L and G;Avns L and H;Avns L and K; Avns L and R; Avns L, A, B; Avns L, A, C; Avns L ,A,G;Avns L,A,H;Avns L,A,K;Avns L,A,R,Av ns L, B, C; Avns L, B, G; Avns L, B, H; Avns L, B, K;Avns L, B, R;Avns L, C, G;Avns L, C, H;Avns L, C, K; Avns L, C, R; Avns L, G, H; Avns L, G, K; A vns L, G, R; Avns L, H, K; Avns L, H, R; Avns L, K ,R;Avns L,A,B,C;Avns L,A,B,G;Avns L,A,B, C, H; Avns L, A, B, C, K; Avns L, A, B, C, R; Avns L ,A,C,G;Avns L,A,C,H;Avns L,B,C,G;Avns L, B, C, H; Avns L, B, C, K; Avns L, B, C, R; Avns L, C ,G,H;Avns L,C,G,K;Avns L,C,G,R;Avns L,G, H, K; Avns L, G, H, R and Avns L, H, K, R.

[0100] In addition, avenanthramide L or an oat extract containing avenanthramide L has Avenathramides other than nanthramides A, B, C, G, H, K, L and R, e.g., Table Avenanthramides D, E, FU, X, Y (also called 2), AA, as specified in 1 , CC or OO.

[0101] Particularly preferred combinations are Avns L and A; Avns L and B; Avns L and C; A vns L and G; Avns L and H; Avns L and K; and Avns L and R However, the most preferred avenanthramide mixtures are Avns L and A and A / B / C. Very particularly preferred is Avns L in combination with The combination of Avn L and Avn A has a synergistic effect.

[0102] Altering the composition of the solvent can improve the extraction selectivity of the avenanthramide substances to be extracted. and thus altering the composition of the preparation, thereby enhancing or decreasing its biological activity. It is possible to do so.

[0103] In a further preferred variant, avenanthramide L or an ene containing avenanthramide L is The tapir extract may contain the following combination of avenanthramides: Avn L and Compound no. 8 (dihydroavenanthramide D) or Avn L and compound no. 27.

[0104] Surprisingly, avenanthramide L or an oat extract containing avenanthramide L: Extremely interesting biological benefits, e.g. anti-inflammatory, anti-oxidant, anti-itch, anti-irritant and and antiatherogenic activity, and thus is useful for skin protection and in the prevention and treatment of skin diseases. In particular, Avena has been shown to be a useful agent in the treatment of Oat extract containing avenanthramide L or avenanthramide L has been shown to be effective in treating skin diseases, especially the barrier. Associated inflammatory, immunoallergic, atherogenic, dry or hyperproliferative disorders It is an effective agent for the prevention and / or treatment of skin disorders or keratin disorders having This turned out to be the case. Avenanthramide L or NK1R antagonists Use of oat extract containing avenanthramide L

[0105] According to a first aspect, the present invention relates to an antagonist of the neurokinin-1 receptor NK1R. Use of avenanthramide L or an oat extract containing avenanthramide L as a Related.

[0106] Thus, the present invention provides a method for treating neurokinin-1 receptor N A method for inhibiting K1R, comprising administering to a subject avenanthramide L or avenanthramide R A oat extract containing avenanthrmid L was administered to subjects to in an amount sufficient to inhibit the kinin-1 receptor, NK1R.

[0107] Surprisingly, avenanthramide L or an oat extract containing avenanthramide L: The results showed that it has the ability to antagonize the binding of SP at the neurokinin-1 receptor NK1R. It turned out to be true.

[0108] Substance P (SP) is an important mediator of inflammation and therefore plays a major pathogenic role. SP is a member of the tachykinin family of peptides and is known to be involved in the regulation of mammalian As a neurotransmitter or modulator in the peripheral and central nervous systems (CNS) of SP is produced and secreted by nerve fibers and binds to the neurokinin-1 receptor N The neurokinin-1 receptor, NK1R, is a tachykinin receptor that binds to cellular G protein-coupled receptors known to activate intracellular signaling pathways In addition to their production from neurons, SP and its NK The 1-receptor complex binds to different immune cell types, particularly keratinocytes, fibroblasts and mast cells. It is well-expressed in multiple skin cell types involved in the initiation and transmission of itch, including the cytoplasm. It is substantiated.

[0109] In particular, the role of SP in keratinocytes, fibroblasts and mast cells is unclear. It appears primarily to be involved in the induction of inflammation accompanied by pruritus (itching).

[0110] As is increasingly documented, the SP-NK1 receptor system mediates many aspects of Induce or modulate the immune response. Activation of the neurokinin-1 receptor NK1R , phospholipase C (PLC) / inositol-1,4,5-triphosphate (IP3) dependent Sexual Ca 2+ - may induce signaling pathways that result in proinflammatory Inflammation occurs through the production of cytokines, e.g., interleukins. Both receptors For example, it is involved in the induction and maintenance of pruritus. Blocking the action of SP through the inflammatory component of skin disorders, particularly skin disorders that have an inflammatory component, is a promising strategy. It has emerged as a promising therapeutic avenue for treatment.

[0111] The ability of avenanthramide L to inhibit the neurokinin-1 receptor NK1R is shown in Example 1. As such, this can be demonstrated using an assay in human recombinant CHO cells.

[0112] Surprisingly, Avenanthramide L was found to be effective at different concentrations of 100, 10, 1 and 0.1 ppm. Avenanthramide L is approximately twice as active as avenanthramide A in each of the above. Surprisingly, the known synthetic neurokinin-1 receptor NK1R antagonist dihydrochloride It is more active than avenanthramide D.

[0113] Avenanthramide C is approximately twice as active as avenanthramide L, but is extremely unstable. whereas avenanthramide L, as demonstrated in Example 2 below, It is significantly less susceptible to degradation by oxygen and exposure to temperature.

[0114] The use of Avenanthramide L according to the present invention has been shown to be effective in treating neuropathy, as described in the above test. It shows significant activity against the neurokinin-1 receptor NK1R and the neurokinin-1 receptor N For the treatment of diseases in which K1R is implicated, in particular for skin care, scalp care, hair care, As a cosmetic for nail care and / or for skin conditions, intolerance and sensitivity Skin, skin irritation, skin redness, wheals, pruritus (itching), skin aging, wrinkle formation, skin volume loss Loss of elasticity, pigmentation spots, pigmentation abnormalities, dry skin, i.e. dry skin that requires moisturizing. In the prevention and / or treatment of dry skin or in the treatment of skin or keratinous disorders, in particular burrs associated with inflammatory, immunoallergic, atherogenic, dry or hyperproliferative In the prevention and / or treatment of skin or keratinopathy having a sexual component This is considered a promising avenue for use as a medicine.

[0115] Avenanthramide L also has the same activity as avenanthramide A and avenanthramide B, as demonstrated in Example 2. It is significantly less degradable than C and C. To induce the expression of small heat shock proteins or to induce the expression of CD44 Use of avenanthramide L or an oat extract containing avenanthramide L - Patents.com

[0116] According to a second aspect, the present invention relates to a method for the expression and / or genetic modification of small heat shock proteins. To induce expression of CD44 and / or to induce gene expression. Use of avenanthramide L or an oat extract containing avenanthramide L for the treatment of .

[0117] Thus, the present invention provides a method for inhibiting the expression of small heat shock proteins in a subject in need thereof. To induce expression and / or gene expression of CD44 A method for inducing gene expression, comprising administering to a subject avenanthramide L or avenanthramide B. The oat extract containing thoramide L was administered to subjects to evaluate the expression and function of small heat shock proteins. To induce expression of CD44 and / or genes, or to induce expression of CD44 and / or genes in an amount sufficient to induce expression.

[0118] Surprisingly, avenanthramide L or an oat extract containing avenanthramide L: Ability to induce expression of small heat shock proteins (sHSPs) and / or gene expression It turned out that it did.

[0119] Organisms and cells express a group of proteins called heat shock proteins (HSPs). By selectively upregulating Responding to pathophysiological stress. HSPs stabilize new proteins and ensure their correct folding. or help proteins that have been damaged by cellular stress to refold, Small heat shock proteins (sHSPs) are molecular chaperones that prevent apoptosis. , a ubiquitous ATP-independent molecular chaperone with low molecular mass (12-43 kDa) HSPs are an old family that exists in the After exposure to α-glucose (usually for 1 hour or longer), these expressions are increased, Dramatic upregulation of heat shock proteins is a key part of the heat shock response. It is primarily induced by heat shock factors (HSFs).

[0120] The hypothesis that HSPs protect cells from heat damage is supported by the following facts: 1) HSP expression occurs in parallel with the development and decline of thermotolerance (heat-induced inactivation) 2) Mutation or inactivation of HSPs impairs the ability of cells to survive at high temperatures. 3) overexpression of HSPs can often improve the ability of cells to withstand high temperatures. The use of Avn L to induce heat shock proteins has not been previously described. do not have.

[0121] Based on their molecular mass, these proteins are divided into six major families: SP100, HSP90, HSP70, HSP60, HSP40 and small heat shock tan sHSPs are classified as sHSPs with subunit molecular masses of 12 to 43 kD. Examples of small heat shock proteins include HSPB1, HSPB2 and HSP B3 (HSP27), HSPB4 (αA-crystallin), HSPB5 (αB-crystallin) phosphorylation), HSPB6 (HSP20) and HSPB8 (HSP22).

[0122] Extensive studies have demonstrated that the majority of sHSPs, and in particular αA-crystallin, are cellular proteins. binds to non-denatured proteins under stress conditions that result in protein unfolding, Thus, by protecting cells from irreversible protein aggregation damage, ATP They demonstrated that the protein / peptide can act as a molecular chaperone. In addition to the chaperone-like activity of the molecule in preventing the aggregation of sHSPs, e.g., HSP2 7 and αB-crystallin are also involved in a variety of cellular functions, e.g., stress resistance, protein synthesis, and Protein folding, protein degradation, maintenance of cytoskeletal integrity, cell death, differentiation, cell cycle as well as being involved in signal transduction and development. Members of the sHSP family are involved in the heart, Includes pancreatic and neuroprotective, potent anti-apoptotic activity, pro-angiogenic properties and interactions In addition to this, small heat shock proteins also stimulate immune receptors. It can also identify the correct folding of proteins involved in proinflammatory signaling pathways. This is important in

[0123] Human sHSPs are characterized by their heat-induced expression, tissue and subcellular localization, structure, and substrate preferences. These differences lead to the distinction between human sHSPs, Different types of protection from acute and chronic (disease-related) stress Demonstrates the ability to

[0124] sHSP27 (HSPB1, HSPB2, HSPB3), as identified above; αB-crystallin (CRYAB / HSPB5) is involved in irreversible transcriptional regulation, especially under stress conditions. Acts as an ATP-independent molecular chaperone that protects cells from damage caused by protein aggregation Normally, sHSPs are aggregation-prone proteins that arise during various stress conditions. HSP27 (HSPB2) stabilizes early unfolding intermediates of proteins. In various cells and tissues, for example in the epidermis and skin, even without prior stress stimulation HSP27 exerts its chaperone function as a large oligomeric complex. The inducibility of HSP27 decreases with age. In addition to its chaperone function, HSP27 also plays a key role in SP27 is linked to the skin barrier: its expression correlates with keratinocyte differentiation and is a basal The differentiation of keratinocytes leads to the formation of the keratinized layer of the skin. This is important for the formation of an excellent epidermal barrier. Associated with hyperkeratosis and misprocessing of filaggrin. αB-crystallin (HspB5) is involved in many It is constitutively expressed in tissues and has anti-apoptotic properties and chaperone activity. B-crystallin forms oligomers with other HSPs, namely HSP27. HSP27 and αB-crystallin (CRYAB) are involved in the stratum corneum and It is localized in healthy skin in the spinous layer.

[0125] Small heat shock protein HSP27 (HSPB2) and αB-crystallin (CRY The ability of avenanthramide L to upregulate AB) can be demonstrated by the following Example 3. .

[0126] The results surprisingly showed that avenanthramide L inhibited the activity of small heat shock proteins at 100 μM. Upregulates protein HSP27 (HSPB2) and αB-crystallin (CRYAB) However, the large heat shock proteins HSP90AA1 and HSP90AB1 were not affected. In addition, when tested at the same test concentrations, avenanthrami DoL upregulates small heat shock proteins more effectively than avenanthramide A.

[0127] Thus, in a preferred variant of the second aspect of the invention, avenanthramide L or avenanthramide L is Small heat shock proteins upregulated by oat extract containing ensulamide L were H SP27 or αB-crystallin (CRYAB).

[0128] The use of avenanthramide L according to the present invention shows significant activity in the above-mentioned tests, Thus, as a physiological response to mediate repair mechanisms, to reduce cellular damage, In addition, it is believed to be useful in the formation of an excellent epidermal barrier. Induction of protein expression in human skin and hair follicles is mediated by environmental, metabolic or pathophysiological stress. and may be an important mechanism for protecting the nail.

[0129] In addition, avenanthramide L or an oat extract preparation containing avenanthramide L was found to be effective in preventing CD It was subsequently found that the 44 genes have the ability to induce expression and / or gene expression. It is.

[0130] CD44 is the best-studied hyaluronan (HA) receptor and is expressed on keratinocytes. It is the major receptor for hyaluronan on the cell surface. Matrix hyaluronan is the major receptor for hyaluronan on the cell surface of most mammalian It is the major glycosaminoglycan in the extracellular matrix (ECM) of tissues, including the epidermis and dermis. HA is a non-glycan that is involved in several epidermal functions in the skin. Downregulation of CD44 (using CD44 siRNA) in nasocytes also supports HA-mediated keratinocyte proliferation and differentiation. Significantly inhibits tinocyte differentiation and lipid synthesis [LY Bourguignon et al. , J. Invest. Dermatol., 2006, pp. 1356-1365].

[0131] CD44 is generally involved in promoting the proliferation and migration of cells in tissues that contain abundant hyaluronan. HA levels and / or HA interaction with CD44 regulate cell differentiation. can regulate (e.g., keratinization of epidermal keratinocytes and myofibroblast proliferation of fibroblasts) During normal tissue homeostasis, hyaluronan synthesis in the epidermis and Decomposition is active, but balanced. However, this homeostasis is disrupted by invasion, e.g. For example, epidermal hirsutism occurs whenever the epidermis is perturbed by trauma, barrier disruption, or UVB irradiation. The amount of alpha-aminobutyric acid in the cells is rapidly increased. Hyaluronan accumulation is closely correlated with cell viability. Hyaluronan, acting together with its receptor CD44, regulates cell survival. Supporting this, stimulated HA synthesis via upregulated HA synthase expression was observed in ex vivo tissues. This is a unique feature of wound-induced keratinocyte activation and may be involved in a proper healing response. CD44 also appears to have a role in limiting inflammatory responses. This has also been shown in models of inflammation.

[0132] The aged epidermis is often characterized by abnormalities in barrier function and loss of lipid synthesis. Epidermal dysfunction and abnormal keratinocyte activity in aged skin are often exacerbated leading to clinical consequences (e.g. epidermal thinning (atrophy), barrier dysfunction, xerosis / dry skin) Recent studies have shown that abnormal HA metabolism plays a key role in skin aging. Involved in changes associated with keratinocyte activity during wound healing, permeability barrier homeostasis, and wound healing It makes it clear that you will get

[0133] The ability of avenanthramide L to upregulate the expression of CD44 is demonstrated in Example 4 below. It is possible.

[0134] Surprisingly, at 100 μM, avenanthramide L upregulates CD44 expression On the other hand, the results show that avenanthramide A has no effect at the same tested concentrations. .

[0135] The use of avenanthramide L according to the present invention showed significant activity in the above-mentioned tests, and Thus, HA / CD44-mediated activities, such as cell differentiation, proliferation and migration, barrier homeostasis, It is believed to be useful as a physiological response to stasis, skin hydration and wound healing. In addition, induction of CD44 expression has been shown to protect human skin, hair and nails from environmental, metabolic and other stresses. may be an important mechanism for protection against pathophysiological stress. Avenanthramide L or β-lactam as an antioxidant or to induce the expression of BLVRB Use of oat extract containing avenanthramide L

[0136] According to a third aspect, the present invention provides a method for the treatment of osteoarthritis, comprising administering to the patient a therapeutically effective amount of a steroid hormone, said method comprising administering to the patient a therapeutically effective amount of a steroid hormone, said steroid hormone being effective in treating osteoarthritis ... Use of avenanthramide L or an oat extract containing avenanthramide L for the treatment of do.

[0137] Thus, the present invention provides a method for inhibiting ROS formation in a subject in need thereof. The method includes administering to a subject avenanthramide L or an oat extract containing avenanthramide L. and administering to the subject an extract in an amount sufficient to inhibit ROS formation in the subject. do.

[0138] The term "antioxidant" as used herein refers to an agent that inhibits the oxidation of oxidizable substrate molecules (e.g., In a mixture or structure containing an oxidizable biological molecule or an oxidizable indicator, In some cases, the oxidation of an oxidizable substrate molecule is significantly delayed, prevented, or even inhibited. Antioxidants are compounds or compositions that can inhibit the release of biologically significant reactive free radicals or other antioxidants. By scavenging reactive oxygen species or preventing their formation or catalyze the conversion of free radicals or other reactive oxygen species to less reactive species. It can be acted on by converting it into

[0139] Surprisingly, avenanthramide L or an oat extract containing avenanthramide L: As a result, it was found to have excellent radical scavenging activity and therefore significant antioxidant capacity. That is what he did.

[0140] In a biological context, reactive oxygen species (ROS) are natural by-products of the normal metabolism of oxygen. They are formed as endothelial cells and have important roles in cell signaling and homeostasis. However, upon environmental stress (e.g., exposure to UV or heat), ROS levels Cumulatively, this can increase dramatically, a phenomenon known as oxidative stress.

[0141] Oxidative stress occurs when excess ROS are produced in cells, which overwhelm normal antioxidant capacity. This occurs when either the immune system is damaged (can cause inflammation) or when antioxidant defense mechanisms are impaired. Oxygen species (ROS) are chemically reactive species that contain oxygen. Examples of ROS include And superoxide anion (O2 ●- ), hydroxyl (OH ● ), peroxyl ( RO2 ● )Alkoxyl(RO ● ) radicals, and non-radical compounds, e.g., peroxides These include hydrogen (H2O2), hypochlorous acid (HOCl) and organic peroxides, which are Endogenous sources (e.g., mitochondrial electron transport chain, cytochrome P450 monooxygenase oxidase, and NADPH oxidase), or from exogenous sources (e.g., pollutants, drugs, ROS toxicity can occur from either xenobiotics or radiation. Affects components and causes significant damage to proteins, lipids and DNA, inflammation, cells and tissues This leads to damage as well as apoptosis.

[0142] Antioxidants are substances that protect cells from oxidative damage and thus reduce the production of reactive oxygen species (ROS). It is a substance that helps prevent or alleviate some chronic diseases caused by Several early studies have reported significant antioxidant activity in oat extracts. Several compositions containing quavenanthramide or derivatives have been shown to have these antioxidant and and anti-aging activity for use in cosmetics, nutraceuticals and therapeutic preparations. However, the specific components in the extract that are responsible for this activity have not been identified. The study synthesized the three most abundant avenanthramides A, B, and C. We isolated and purified them and measured their antioxidant activities in an in vitro system. Nanthramide showed antioxidant activity. The order of antioxidant activity was Avn C>Avn B>A. It turned out to be vn A.

[0143] Oxidative stress plays a key role in the pathogenesis and progression of major human diseases, including inflammatory diseases. There is strong evidence that it also plays a role in aging. Not only does it directly damage the cellular structure of the skin, it also increases inflammation of the skin and causes skin burrs. This weakens the immune system and allows infection by microbial pathogens. According to the study, oxidative damage initiated by reactive oxygen species (ROS) is a hallmark of aging. This is a major driver of decline.

[0144] Ability of Avenanthramide L to scavenge radicals or inhibit radical formation; And the antioxidant activity of the cells can be demonstrated by Examples 5 and 6 below.

[0145] The ABTS assay was compared to Trolox (a water-soluble vitamin E analogue) standard. To measure the relative ability of antioxidants to scavenge the ABTS radicals formed in the aqueous phase, The stable green-blue radical cationic chromophore 2,2'-azinobis(3- Ethyl benzothiazoline-6-sulfonate (ABTS ●+ ) is a strong oxidizing agent (e.g. , potassium permanganate or potassium persulfate) by reaction with ABTS salts It is produced and has absorption maxima at 414, 645, 734 and 815 nm. The reduction of the blue-green ABTS radical by antioxidants is due to its characteristic long-wave absorption. It is measured by the suppression of the absorption spectrum.

[0146] As demonstrated in Example 5 below, avenanthramide A showed similar (concentration) avenans with antioxidant activity (at a concentration of 5 μM) or even improved (at a concentration of 10 μM) Lamido-L exhibits excellent antioxidant capacity due to its radical scavenging activity, and thus has beneficial antioxidant properties. The results of the ABTS assay indicate that it acts as an oxidizing agent.

[0147] Avenanthramide L, when used at a concentration of 5 μM, was determined using the ABTS assay. As shown in the above, the preferred embodiment of the present invention has a radical scavenging activity of at least 40%. In the new variant, avenanthramide L, when used at a concentration of 10 μM, has been shown to inhibit at least 70 % radical scavenging activity.

[0148] The DCF-DA assay detects 2',7'-dichlorophenyl phosphate (DPP) in the presence of reactive oxygen species (ROS). Difluorofluorescein diacetate (DCF-DA) is synthesized as highly fluorescent compounds 2',7' -Oxidative stress by detecting its oxidation to dichlorofluorescein (DCF) The DCF-DA assay is a fluorometric quantitative microplate assay for the detection of , making it possible to determine the cellular antioxidant activity of a substance.

[0149] The results of the DCF-DA assay surprisingly showed that the same test concentration of 100 μg / mL was Avenanthramide L showed higher antioxidant activity than avenanthramide A in M. It is clearly shown.

[0150] Avenanthramide L or oat extract containing avenanthramide L is a BLVRB It has also been found that the IL-16A-binding domain has the ability to induce expression and / or gene expression. be.

[0151] Biliverdin reductase is an enzyme found in all tissues under normal conditions. In humans, two isozymes, each encoded by its own gene, , biliverdin reductase A (BLVRA) and biliverdin reductase B (BLVRB) Biliverdin reductase converts biliverdin to bilirubin, which Bilirubin is an intracellular antioxidant and free radical scavenger that breaks down the chains. Biliverdin is converted back to biliverdin through the action of reactive oxygen species (ROS). Thus, this cycle allows for the neutralization of ROS and thus the reduction of biliverdin reductase. The original enzyme function is thought to be cytoprotective. B. Bai et al. [J. Photochem Photobiol.B, 2015, Vol. 144, pp. 35-41] is biliverdin Protects against UVB radiation-induced skin damage mediated by its antioxidant mechanism and cell signaling regulatory effects This suggests that it plays a role in preventing photodamage.

[0152] The ability of avenanthramide L to upregulate the gene expression of BLVRB is shown in Example 4 below. This can be demonstrated by:

[0153] Surprisingly, avenanthramide L upregulated the gene expression of BLVRB at 100 μM. whereas avenanthramide A had no effect at the same test concentrations. The results are showing. The use of avenanthramide L according to the present invention has excellent radical scavenging activity and Expression of BLVRB and / or upregulation of gene expression, and therefore significant antioxidant potential and therefore may be useful as antioxidants. In addition, antioxidant capacity is important in the prevention of , important for protecting human skin, hair and nails from metabolic or pathophysiological stresses. This may be an important mechanism.

[0154] The compound of the present invention, i.e., avenanthramide L or an ene compound containing avenanthramide L Tapir extract is an established beneficial neurokinin-1 receptor NK1R antagonist. and expression of small heat shock proteins and / or genes. Inducing or inducing expression and / or gene expression of CD44, or These promising properties make the compounds of the present invention suitable for use in cosmetic formulations. It has been proven to be useful both therapeutically and for medical purposes.

[0155] Thus, one embodiment of the present invention is avenanthramide L or avenanthramide L Cosmetics for skin care, scalp care, hair care and nail care of oat extract containing For use as a skin condition, intolerant and sensitive skin, skin irritation, skin redness, wheals , pruritus (itching), skin aging, wrinkle formation, loss of skin volume, loss of skin elasticity, pigmentation spots , pigmentation disorders, dry skin, i.e., prevention and / or treatment of dry skin requiring skin moisturization It is for use in

[0156] Another aspect of the present invention is the use of avenanthramide L or avenanthramide L for use as a medicament. It relates to an oat extract containing suramid L.

[0157] Due to the above-mentioned promising properties, avenanthramide L or ember containing avenanthramide L is The extract is effective in treating skin and keratin diseases, especially those related to the barrier, inflammatory and immunological allergies. Skin or keratinopathy with atherogenic, atherogenic, xerogenic or hyperproliferative component In particular, avenin is useful in the prevention and / or treatment of diseases. Oat extracts containing avenanthramide L or avenanthramide L are effective in treating skin diseases, especially itching and / or pruritus. or is useful for being beneficial in the prevention and / or treatment of skin conditions associated with pruritus. Examples of such skin disorders include eczema, psoriasis, seborrhea, dermatitis, erythema, and pruritus (itchy skin). ), otitis, xerosis, inflammation, irritation, fibrosis, lichen planus, pityriasis rosea, tinea versicolor, autoimmune Bullous diseases, urticarial, angiodermal and allergic skin reactions, and wounds Healing is mentioned.

[0158] Thus, another aspect of the present invention relates to a method for treating a skin or keratinopathy, particularly a barrier-related disease, Has inflammatory, immunoallergic, atherogenic, xerogenic or hyperproliferative components Avenant for use in the prevention and / or treatment of skin or keratinous diseases The present invention relates to an oat extract containing avenanthramide L or avenanthramide L.

[0159] Thus, the present invention relates to a method for treating a skin disease or keratinopathy, particularly a keratinopathy, in a subject in need thereof. have barrier-related, inflammatory, immunoallergic, dryness or hyperproliferative components The present invention relates to a method for treating a skin or keratinopathy, the method comprising administering to a subject a therapeutically effective amount of abetaxin. The oat extract containing nanthramide L or avenanthramide L was administered to subjects to -Inhibits the neurokinin-1 receptor NK1 and / or expression of small heat shock proteins or in an amount sufficient to induce expression of CD44 and / or inhibit ROS formation. The present invention relates to a method comprising administering

[0160] In a preferred variant of the invention, avenanthramide L or an endothelial containing avenanthramide L is Extracts of rambutan are useful for the prevention and / or treatment of pruritus (itch). do.

[0161] Chronic pruritus is a common symptom associated with a variety of skin conditions and systemic diseases and may Chronic pruritus is characterized by clinical symptoms (e.g., inflammatory / inflammation) and therefore no known underlying condition. Combined with the presence of inflammatory or normal / non-inflammatory skin and / or secondary scratch lesions and underlying causes (e.g., dermatologic, systemic, neurological, psychosomatic, mixed or SP and the neurokinin-1 receptor NK1R are involved in itch-related disorders. It has been well documented that IL-1 plays an important role in signal transduction. This is supported by studies demonstrating that: (i) the neurokinin-1 receptor, NK1R, , in multiple cell types in the skin, e.g., keratinocytes and mast cells, as well as in the CNS (ii) Neurokinin-1 is expressed widely in the epidermis in many pruritic skin disease conditions; There is overexpression of the receptor NK1R, resulting in a greater number of SP-expressing nerve fibers and inflammatory cells. found in the skin; and (iii) neurokinin-1 receptor NK1R antagonists Blocking the neurokinin-1 receptor NK1R using is prevented and thus the itching is reduced.

[0162] Avenanthramide L or Avenanthramide L-containing The use of oat extracts is to improve the efficacy of the substance by adding a therapeutically effective amount of the substance or preparation. Each corresponds to a method for imparting therapeutic activity.

[0163] Within the context of the present invention, an effective amount of a composition is an amount that is sufficient to provide a benefit, e.g., a disorder, disease or condition to be treated. The amount of each active ingredient is sufficient to result in a reduction in the symptoms associated with the condition. When applied to a combination or preparation, the term refers to a combination of active ingredients that provides a benefit. Refers to the amount of minutes.

[0164] Another aspect of the present invention relates to a method for the skin care of said skin condition or said skin disorder or keratin disorder. or food, dietary supplements, cosmetics, pharmaceuticals and veterinary preparations useful for the prevention and / or treatment of Avenanthramide L or an oat extract containing avenanthramide L for preparing a product. Regarding the use of the product.

[0165] Avenanthramide L or oat extract containing avenanthramide L is a conventional food, It can be easily incorporated into dietary supplements, cosmetic, pharmaceutical or veterinary preparations.

[0166] Within this context, avenanthramide L or an oat extract containing avenanthramide L is The cosmetic and / or dermatological or keratin preparations are conventional in composition. and for the treatment of skin, hair and / or nails within the context of dermatological or keratinological treatments or cosmetic care. It can function to treat

[0167] Skin conditions or diseases are often characterized by dry skin, scratchy skin, skin lesions or Furthermore, it is accompanied by inflammation, so avenanthramide L or oats containing avenanthramide L are recommended. Cosmetic and / or pharmaceutical preparations containing the extract are particularly advantageous in that they have skin moisturizing and / or or moisture retaining substances, cooling agents, osmolytes, keratolytic substances, nutrients, anti-inflammatory, anti Contains antibacterial or antifungal substances and / or redness-relieving or itching-relieving properties Contains substances that may cause skin irritation and / or emollients.

[0168] Within this context, avenanthramide L or an oat extract containing avenanthramide L is Other active substances, for example, optionally other synergistic enhancing or even supplementary substances, e.g. For example, anti-inflammatory, anti-bacterial or anti-fungal properties, as described and exemplified in detail below. substances with redness-relieving or itching-relieving properties, skin softeners, moisturizers and / or or cooling agents and / or antioxidants, preservatives, (metal) chelating agents, penetration enhancers, and and / or for cosmetic or pharma- ceutical use in combination with pharma- ceutical acceptable excipients. It is possible, and in some cases even advantageous, to do so.

[0169] Itching occurs with particular intensity, especially if the skin is dry. The use of a skin moisture regulating agent can significantly alleviate itching. Within the context of use, avenanthramide L or an oat extract containing avenanthramide L Cosmetic and / or pharmaceutical preparations which contain also particularly advantageously one or more moisturizing and conditioning agents. It may contain agents and / or moisture retaining substances and may be used in cosmetics and / or pharmaceuticals. Any moisturizing agent that is suitable or conventional for the application, e.g., sodium lactate, urea Alkanes and derivatives, alcohols, alkanediols or alkanes containing 3 to 12 carbon atoms Alkantriols, preferably C3-C10-alkanediols and C3-C10-alkanediols Glucantriol can be used, and more preferably the moisturizing agent is glycerol. , 1,2-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol Coal, 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol ethanol and 1,2-decanediol, collagen, elastin or hyaluronic acid, azide Diacyl phthalate, Vaseline, Urocanic acid, Lecithin, Panthenol, Phytantriol lycopene, (pseudo)ceramide, glycosphingolipid, cholesterol, phytosulfate Tetraterol, chitosan, chondroitin sulfate, lanolin, lanolin esters, amino acids, Sulfahydroxy acids (e.g., citric acid, lactic acid, malic acid) and their derivatives, monosaccharides, disaccharides Sugars and oligosaccharides, such as glucose, galactose, fructose, mannose, broth and lactose, polysugars such as β-glucans, especially oat or Yeast-derived 1,3-1,4-β-glucan, alpha-hydroxy fatty acids, triterpenes It consists of an acid, such as betulinic acid or ursolic acid, and an algae extract.

[0170] Depending on the substance, the concentration of the water retention regulator used may vary depending on the type of ready-to-use cosmetic or pharmaceutical product. Between 0.1 and 10% (m / m), preferably 0.5 to 5%, based on the total weight of the final product. (m / m). These data are especially relevant for the advantageously used diols, e.g. For example, hexylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,2-Octanediol and 1,2-Decanediol, as well as 1,2-Hexanediol This applies to a mixture of ethanol and 1,2-octanediol.

[0171] The use of cooling agents in cosmetics and medicines can relieve itching. Within the context of the use according to the invention, avenanthramide L or avenanthramide L-containing Cosmetic and / or pharmaceutical preparations comprising an oat extract may also be particularly advantageously characterized in that they contain one or more The composition may contain one or more cooling agents. Examples of suitable individual cooling agents are listed below. Those skilled in the art will recognize that many other cooling agents are readily available. The listed cooling agents may be used in combination with each other. Available: l-menthol, d-menthol, racemic menthol, menthone glycerol a Setal (trade name: Frescolat® MGA), Menthyl Lactate (trade name: Frescolat® ML; menthyl lactate is preferably l-menthyl lactate, especially l-menthyl lactate), substituted menthyl-3-carboxamides (e.g., menthyl -3-carboxylic acid N-ethylamide), 2-isopropyl-N-2,3-trimethylbutadiene Amides, Substituted Cyclohexanecarboxamides, 3-Menthoxypropane-1,2-diamines 2-Hydroxyethyl Menthyl Carbonate, 2-Hydroxypropyl Menthyl Carbonate Carbonate, N-acetylglycine menthyl ester, isopulegol, menthyl oxalate ethylamide (trade name: Frescolat® X-cool), hydroxy Menthyl carboxylic acid esters (e.g., menthyl 3-hydroxybutyrate), succinic acid Monomenthyl, 2-mercaptocyclodecanone, menthyl 2-pyrrolidin-5-oncal carboxylate, 2,3-dihydroxy-p-menthane, 3,3,5-trimethylcyclohexane Xanone glycerol ketal, 3-menthyl-3,6-di- and trioxaalkano ate, 3-menthyl methoxyacetate and icilin.

[0172] The preferred cooling agents based on certain synergistic effects are l-menthol, d-menthol, racemic Mymenthol, Menthone Glycerol Acetal (trade name: Frescolat (registered trademark) (Mark: MGA), menthyl lactate (preferably l-menthyl lactate, particularly l-menthyl lactate) (trade name: Frescolat® ML), substituted menthyl-3-carboxamide (e.g., menthyl-3-carboxylic acid N-ethylamide), 2-isopropyl-N-2, 3-Trimethylbutanamide, Substituted cyclohexanecarboxamide, 3-menthoxy- propane-1,2-diol, 2-hydroxyethyl menthyl carbonate, 2-hydroxy Dipropyl menthyl carbonate, oxalic acid menthyl ethylamide (trade name: Fresc olat® X-cool and isopulegol. The agent is l-menthol, racemic menthol, menthone glycerol acetal (trade name: Frescolat® MGA), menthyl lactate (preferably l-menthyl lactate , in particular l-menthyl lactate (trade name: Frescolat® ML), 3-menthyl lactate, 2-Hydroxyethyl Menthyl Carbonate, Menthyl ethyl oxalate (trade name: Frescolat® X-cool) and 2-hydroxy-propyl menthyl carbonate.

[0173] Very particularly preferred cooling agents are l-menthol, menthone glycerol acetal ( Trade name: Frescolat (registered trademark) MGA), Menthyl Ethyl Oxalate (trade name) Frescolat® X-cool) and menthyl lactate (preferably l-menthyl lactate, in particular l-menthyl lactate (trade name: Frescolat® )ML).

[0174] Depending on the substance, the concentration of the freshener used may vary depending on the composition of the ready-to-use cosmetic or pharmaceutical product. It is preferably between 0.01 and 20% by weight, particularly preferably between 0.1 and 5% by weight, based on the total weight of the composition. The amount is between 100% and 200%.

[0175] Within the context of the use according to the invention, avenanthramide L or an endothelial agent containing avenanthramide L is Cosmetic and / or pharmaceutical preparations containing the extract of burdock are particularly advantageous in that they are Examples of osmolytes that can be mentioned here are As sugar alcohols (myoinositol, mannitol, sorbitol), quaternary amines Taurine, choline, betaine, betaine glycine, ectoine, diglyceroside, phosphate, phosphorylcholine or glycerophosphorylcholine, amino acids, e.g. For example, glutamine, glycine, alanine, glutamate, aspartate or proline, Phosphatidylcholine, phosphatidylinositol, inorganic phosphates, and the above compounds Polymers of the group including, for example, proteins, peptides, polyamino acids and polyols. All osmolytes simultaneously have a skin moisturizing effect.

[0176] Preferably, the keratolytic substance is also, particularly advantageously, avenanthramide L or avenant. Use in cosmetic and / or pharmaceutical preparations containing oat extract containing suramid L Keratolytic compounds include a large group of alpha hydroxy acids. For example, salicylic acid is preferably used.

[0177] For example, for the topical cosmetic or pharmaceutical treatment of dry and / or itchy skin; Cosmetics containing avenanthramide L or an oat extract containing avenanthramide L, and / or in pharmaceutical preparations, a particularly high proportion of nutritional substances is also due to lipophilic components It is particularly advantageous for reducing transepidermal water loss. Alternatively, the pharmaceutical preparation may comprise one or more nutritious animal and / or vegetable fats, e.g. and oils, e.g., olive oil, sunflower oil, refined soybean oil, palm oil, sesame oil, naphtha oil, Seed oil, almond oil, borage oil, evening primrose oil, coconut oil, shea butter, jojoba oil, Sperm whale oil, tallow, beef foot oil and lard, and optionally other nutrients The components include, for example, aliphatic alcohols having 8 to 30 carbon atoms. The fatty alcohols used may be either saturated or unsaturated and may be straight-chained or branched. The mixtures according to the invention can be particularly preferably combined with The nutrients also include ceramides, which significantly improve the water retention capacity of the stratum corneum. -Synthesis of acylsphingosines (fatty acid amides of sphingosine) or such lipids Ceramides, which are understood to mean analogues (so-called pseudoceramides); phospholipids, e.g. For example, soy lecithin, egg lecithin and cephalin; as well as petrolatum, paraffin oil and and silicone oils, the latter including, among others, dialkyl- and alkylaryl siloxanes. For example, dimethylpolysiloxane and methylphenylpolysiloxane and their derivatives. Includes alkoxylated and quaternized derivatives of.

[0178] Within the context of the use according to the invention, avenanthramide L or a preparation containing avenanthramide L is The cosmetic and / or pharmaceutical preparations containing the product may also contain one or more anti-inflammatory agents. Contains substances that reduce redness and / or itch These in this context include all anti-inflammatory active substances, as well as redness and and / or Contains active substances commonly used: steroidal anti-inflammatory of the corticosteroid class Substances such as hydrocortisone, hydrocortisone derivatives such as hydrocortisone 17-Butyrate, Dexamethasone, Dexamethasone Phosphate, Methylprednisolone Anti-inflammatory compounds or compounds that relieve redness and / or itching. Other steroidal anti-inflammatory agents may also be added to this list. It is also possible to use non-steroidal anti-inflammatory drugs. Examples include oxicams, such as piroxicam or tenoxicam; salicylates, For example, aspirin, Disalcid®, Solprin®, or fendosal; acetic acid derivatives, e.g., diclofenac, fenclofenac, indole methacin, sulindac, tolmetin or clindanac; fenamic acids, such as mefe namic acid, meclofenamic acid, flufenamic acid or niflumic acid; propionic acid derivatives, For example, ibuprofen, naproxen or benoxaprofen; or pyrazole. phenylbutazone, oxyphenylbutazone, febrifurazone or azapropanol. Possible options include natural anti-inflammatory substances or anti-redness and / or The use of substances that relieve itching. Plant extracts, special highly active plant extract fractions. and high purity active substances isolated from plant extracts can be used. Loe vera, Commiphora species, Rubia species, Willow, Fireweed, Ginger, G Lycyrrhiza species, Rubus species, Oat, Calendula, Arnica, Centella asiatica Jones's Wort, Honeysuckle, Rosemary, Passiflora incarn Extracts, fractions and actives from Ipomoea batata, Witch hazel, Ginger or Echinacea quality, as well as pure substances, such as (alpha-)bisabolol, apigenin, apigenin, among others. Pigenin-7-glucoside, gingerols, e.g., [6]-gingerol, paradol For example, [6]-paradol, boswellic acid, phytosterol, glycyrrhizin, Particularly preferred are labridin and licochalcone A. The formulations also contain two or more anti-inflammatory Mixtures of active compounds may be contained.

[0179] Depending on the substance, the concentration of anti-inflammatory compounds that can be used varies from ready-to-use cosmetic products to or the total weight of the final pharmaceutical product, is in the range of 0.005 to 2% (m / m), preferably The preferred range is 0.05 to 0.5% (m / m). or synergistic mixtures of bisabolol with ginger extract or [6]-paradol Applies to things.

[0180] Other antibacterial or antifungal active substances may also be used as avenanthramide L or avenanthramide. Particularly advantageous in cosmetic and / or pharmaceutical preparations containing an oat extract containing L. and are suitable or customary for cosmetic and / or pharmaceutical applications Any antibacterial or antifungal active substance can be used. In addition, other products which are advantageous here include, for example, in particular, triclosan, climbazole, o Octoxyglycerin, Octotropox® (1-hydroxy-4-methyl- 6-(2,4,4-trimethylpentyl)-2(1H)-pyridone 2-aminoethanol salts), chitosan, farnesol, glycerol monolaurate or combinations of the above. which are used inter alia against underarm odor, foot odor or dandruff.

[0181] Within the context of the use according to the invention, avenanthramide L or an endothelial agent containing avenanthramide L is Cosmetic and / or pharmaceutical preparations containing the extract of burdock may also be used to treat one or more skin emollients. and may contain additives suitable or customary for cosmetic and / or pharmaceutical use. Certain optional emollients, such as alpha-bisabolol, azulene, guaiazulene, 18-β-glycyrrhetinic acid, allantoin, aloe vera juice or gel, Hamamel is virginiana (witch hazel), Echinacea species, Centella asiatica, Chamomile, Arnica monatana, Glycyrrhi Extracts of za seeds, algae, seaweed and Calendula officinalis, and vegetable oils, e.g. sweet almond oil, baobab oil, olive oil and panthenol can be used.

[0182] Within the context of the use according to the invention, avenanthramide L or a preparation containing avenanthramide L is Cosmetics and / or pharmaceutical preparations containing the product may also be used as one or more cosmetic products. or pharma- ceutically acceptable excipients, e.g., those conventionally used in such preparations. antioxidants, preservatives, (metal) chelating agents, penetration enhancers, surfactants, milk Colouring agents, perfume oils, defoaming agents, colouring agents, pigments with colouring action, thickeners, surface-active substances, emulsifiers, Plasticizers, other moisturizing and / or moisture-retaining substances, fats, oils, waxes, or cosmetic products Other conventional components of the agent, such as alcohols, polyols, polymers, foam stabilizers, electrolytes, etc. Cosmetics and / or Any conceivable antioxidant suitable or conventionally used for pharmaceutical applications. agents, preservatives, (metal) chelating agents, penetration enhancers, surfactants, emulsifiers, perfume oils, defoamers, Colorants, pigments with coloring action, thickeners, surface-active substances, emulsifiers, plasticizers, other moisturizing and and / or moisture-retaining substances, fats, oils, waxes or other conventional components of cosmetic formulations , for example, alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicones. Corn derivatives may be used herein in accordance with the present invention.

[0183] Particularly preferred is avenanthramide L or an oat extract containing avenanthramide L. For other cosmetic and pharmaceutical excipients, bases and auxiliaries that may be combined, see WO 03 / 069994, WO2004 / 047833 or WO2007 / 062957 Reference may be made to the detailed description.

[0184] Within the context of the use according to the invention, avenanthramide L or an endothelial agent containing avenanthramide L is Cosmetic and / or pharmaceutical preparations containing the extract of sorghum may also contain one or more antioxidants. The composition can particularly advantageously contain a cosmetic agent and is suitable for cosmetic and / or pharmaceutical applications. Any suitable or conventionally used antioxidant may be used. Advantageously, Antioxidants include amino acids (e.g., glycine, histidine, tyrosine, tryptophan) and and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides D,L-carnosine, D-carnosine, L-carnosine and their derivatives carotene (e.g., anserine), carotenoids, carotenes (e.g., α-carotene, β-carotene) , lycopene) and their derivatives, lipoic acid and its derivatives (e.g. dihydrolipoic acid) , gold thioglucose, propylthiouracil and other thiols (e.g. thioredoxin , glutathione, cysteine, cystine, cystamine and their glycosyl, N-amino acids Cetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl oleyl, gamma-linoleyl, cholesteryl and glyceryl esters) and their salts, Dilauryl thiodipropionate, Distearyl thiodipropionate, Thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides, etc.) side and salts) and sulfoximine compounds (e.g. buthionine sulfoximine, homo Cysteine ​​sulfoximine, buthionine sulfone, penta-, hexa-, hepta- sulfoximines) (these are tolerated at very low doses), as well as (metal) chelates. Agents such as α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin, α-hydroxy Hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acids, bile acids, bile extracts, biliary acids, Rubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and These derivatives (e.g., gamma-linolenic acid, linoleic acid, oleic acid), folic acid and its derivatives Conductors, ubiquinone and ubiquinol and their derivatives, vitamin C and its derivatives Ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate vitamin E acetate), tocopherols and their derivatives (e.g. vitamin E acetate), vitamin A and and its derivatives (e.g. vitamin A palmitate), as well as the benzoic acid co-formation of benzoin resin. Niferil, rutin acid and its derivatives, ferulic acid and and its derivatives, butyl hydroxytoluene, butyl hydroxyanisole, nordihydr Loguaric acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, urinary acid and its derivatives, mannose and its derivatives, zinc and its derivatives (e.g. Zn O, ZnSO4), gingerols, e.g. [6]-gingerol, paradols, e.g. [ 6]-paradol, selenium and its derivatives (e.g. selenomethionine), stilbene and and their derivatives (e.g., stilbene oxide, trans-stilbene oxide), As well as derivatives of the active compounds (e.g. salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids), for example those suitable according to the present invention is selected from.

[0185] Within the context of the use according to the invention, avenanthramide L or an endothelial agent containing avenanthramide L is Cosmetic and / or pharmaceutical preparations containing the extract of burdock may also contain one or more or a number of substances, which can be particularly advantageously contained in the composition, for cosmetic and / or pharmaceutical applications. Suitable or customary for the preparation of such compounds are, advantageously, for example, benzoic acid, its esters and salts, among others. Propionic acid and its salts; Salicylic acid and its salts; 2,4-Hexanoic acid (sorbic acid) and its salts; formaldehyde and paraformaldehyde; 2-hydroxybiphenyl Phenyl ethers and their salts;2-Zinc sulfidopyridine N-oxide;Inorganic sulfites. and bisulfite; sodium iodate; chlorobutanol; 4-hydroxybenzoic acid and its salts and esters;Dehydroacetic acid;Formic acid;1,6-bis(4-amidino-2- Bromophenoxy)-n-hexane and its salts; Ethylmercury-(II)-thiosalicyl Sodium salts of acids;Phenylmercury and its salts;10-Undecylenic acid and its salts;5 -Amino-1,3-bis(2-ethylhexyl)-5-methylhexahydropyrimidine; 5-Bromo-5-nitro-1,3-dioxane; 2-Bromo-2-nitro-1,3-propane Pandiol;2,4-Dichlorobenzyl alcohol;N-(4-chlorophenyl)-N '-(3,4-Dichlorophenyl)urea;4-Chloro-m-cresol;2,4,4' -Trichloro-2'-hydroxy-diphenyl ether; 4-chloro-3,5-dimethyl Phenol;1,1'-methylene-bis(3-(1-hydroxymethyl-2,4-dioxa cyimidazolidin-5-yl)urea;Poly(hexamethylene biguanide) hydrochloride; 2-Phenoxyethanol;Hexamethylenetetramine;1-(3-chloroallyl)-3 ,5,7-Triaza-1-azoniaadamantane chloride;1-(4-chloro-phenoxy 1,3 -Bis(hydroxymethyl)-5,5-dimethyl-2,4-imidazolidinedione; Dichloromethane; Octotropirox®; 1,2-Dibromo-2,4-dichloromethane Nobutane; 2,2'-methylene-bis(6-bromo-4-chloro-phenol); Bromo Chlorophene; 5-chloro-2-methyl-3(2H)-isothiazolinone and 2-methyl mixture of ru-3(2H)isothiazolinone with magnesium chloride and magnesium nitrate; 2-Benzyl-4-chlorophenol; 2-Chloroacetamide; Chlorhexidine; Vinegar Chlorhexidine acid;Chlorhexidine gluconate;Chlorhexidine hydrochloride;1-pheno 2-Oxy-propanol;N-Alkyl(C12-C22)trimethylammonium Bromides and chlorides; 4,4-Dimethyl-1,3-oxazolidine; N-Hydroxy Methyl-N-(1,3-di(hydroxymethyl)-2,5-dioxoimidazolidine-4 -yl)-N'-hydroxymethylurea;1,6-bis(4-amidinophenoxy)- n-Hexane and its salts;Glutaraldehyde 5-ethyl-1-aza-3,7-diox Sabicyclo(3.3.0)octane; 3-(4-chlorophenoxy)-1,2-propane Diol; Hyamine; Alkyl (C8-C18) dimethylbenzyl ammonium chloride Alkyl (C8-C18) dimethylbenzyl ammonium bromide; Saccharinic acid ammonium Benzyl dimethyl benzyl ammonium;Benzyl hemiformal;3- Iodo-2-propynyl butylcarbamate;o-cymen-5-ol, or ((Hydro

[0036] Any preservative selected from the group consisting of sodium (hydroxymethyl)amino)acetate, Preservatives may be used.

[0186] Within the context of the use according to the invention, avenanthramide L or an endothelial agent containing avenanthramide L is Cosmetic and / or pharmaceutical preparations containing the extract of burdock may also contain one or more (metal ) Chelating agents may also be included with particular advantage, making them suitable for cosmetic and / or pharmaceutical applications. Any suitable or conventional metal chelating agent may be used. ) Chelating agents include α-hydroxy fatty acids, phytic acid, lactoferrin, and α-hydroxy oxidic acids, such as, inter alia, citric acid, lactic acid and malic acid, as well as humic acid, bile acids, Juice extract, bilirubin, biliverdin or EDTA, EGTA and their derivatives Some examples include:

[0187] Within the context of the use according to the invention, avenanthramide L or an endothelial agent containing avenanthramide L is Cosmetic and / or pharmaceutical preparations containing the extract of sorghum may also contain one or more penetration enhancers. They may also contain promoters with particular advantage, making them suitable or suitable for cosmetic and / or pharmaceutical applications. Any conventional penetration enhancer may be used. The penetration enhancer is used to enhance the absorption of the drug through the skin. The permeability of the active agent may be enhanced. Preferred permeation enhancers include sulfoxides (e.g., diphenyl ethers, methyl sulfoxide, DMSO), fatty acids (e.g. caprylic acid, capric acid, lauric acid , myristic acid, palmitic acid, stearic acid, oleic acid and linoleic acid), fatty acids Esters (e.g. ethyl oleate, ethyl laurate) and fatty alcohols (e.g. Capryl, decyl, lauryl, myristyl, cetyl, stearyl, oleyl, linoleyl alcohol), azone (e.g. laurocapram), pyrrolidone (e.g. 2-pyrrolidone , 2P), alcohols and alkanols (e.g. ethanol, propanol, butanol, alcohol or decanol), glycerol, terpenes (e.g. 1,8-cineole, limonene , menthone, nerolidol, linalool, and menthol), surfactants (e.g., SD S and SLS), urea, and dimethyl isosorbide. Preferred penetration enhancers include 1,2-propanediol (propylene glycol), 1,2 -Butanediol, 1,2-Pentanediol (Hydrolite-5), 1,2-Hexanediol Xanediol (Hydrolite 6), 1,2-heptanediol, 1,2-octanediol Tandiol, 1,2-nonanediol, 1,2-decanediol or 1,2-dodeca Butanediol; 1,3-butanediol (butylene glycol), 1,4-butanediol , 1,1'oxydi-2-propanol (dipropylene glycol) and its isomers; 1,3-Propanediol; Polyols, alcohols; Dimethyl isosorbide (INCI noun);triethyl citrate;butylene carbonate;glycerin carbonate;dipropylene glycol Coal or any mixture of these.

[0188] Within the context of the use according to the invention, avenanthramide L or an endothelial agent containing avenanthramide L is Cosmetic and / or pharmaceutical preparations containing the extract of burdock may also contain, in particular, crystalline or microcrystalline If inorganic solids, such as inorganic micropigments, are incorporated into the preparation, one or more anionic Particularly advantageously they contain ionic, cationic, nonionic and / or amphoteric surfactants. Surfactants are parent compounds capable of solubilizing organic, non-polar substances in water. The hydrophilic portion of a surfactant molecule usually contains a polar functional group, e.g., -COO - , -OSO3 - or -SO3 - where the hydrophobic portion is usually a non-polar hydrocarbon radical. Surfactants are generally classified according to the type and charge of the hydrophilic part of the molecule. can be divided into four groups: anionic surfactants, cationic surfactants; ionic surfactants; and nonionic surfactants.

[0189] Anionic surfactants usually contain carboxylate, sulfate or sulfonate groups. In aqueous solution, they form negatively charged organic Cationic surfactants are essentially cations formed by the presence of quaternary ammonium groups. In aqueous solution, they are characterized exclusively by positively charged organic Amphoteric surfactants contain both anionic and cationic groups and form ions. Thus, depending on the pH value, they behave like anionic or cationic surfactants in aqueous solution. They have a positive charge in a strongly acidic medium and a negative charge in an alkaline medium. At neutral pH, in contrast, they are zwitterions. Polyether chains are non-ionic Typical of surfactants. Nonionic surfactants do not form ions in aqueous media. .

[0190] Anionic surfactants which can be used advantageously include: acyla Amino acids (and their salts), such as acyl glutamates, such as acyl glutamine Sodium Aspartate, Di-TEA-Palmitoyl Aspartate and Caprylic / Capric Acid Monosodium glutamate; acyl peptides, e.g., palmitoyl hydrolyzed milk protein , Sodium Cocoyl Hydrolyzed Soy Protein and Sodium Cocoyl Hydrolyzed Collagen Sodium / potassium; Sarcosinates, e.g., Myristoyl Sarcosine, Lauroyl Sarcosine Cocin TEA, Sodium Lauroyl Sarcosinate and Sodium Cocoyl Sarcosinate; Taurates, such as sodium lauroyl taurate and sodium methyl cocoyl taurate thorium; acyl lactylates, such as lauroyl lactylate and caproyl lactylate alaninates; carboxylic acids and derivatives, e.g., lauric acid, aluminum stearates ammonium, magnesium alkanolates and zinc undecylates; ester carboxylic acids, e.g. For example, calcium stearoyl lactylate, laureth-6 citrate and PEG-4 laureth. Sodium uramide carboxylate; Ether carboxylic acids, such as laureth-13 carboxylate Sodium Cocamide Carboxylate and Sodium PEG-6 Cocamide Carboxylate; Phosphate Esters and Salts , e.g., DEA-oleth-10 phosphate and dilaureth-4 phosphate; sulfonic acids and salts, such as acyl isethionates, e.g. sodium / cocoyl isethionate ammonium; alkylarylsulfonates; alkylsulfonates, e.g., cocomonogly Sodium ceridesulfonate, Sodium olefin (C12-14) sulfonate, Lauryl sulfonate Sodium aryl sulfoacetate and PEG-3 cocamide magnesium sulfate; Sulfosuccinate dioctyl sodium sulfosuccinate, laureth disodium sulfosuccinate Sodium, Disodium Lauryl Sulfosuccinate and Undecylenamid M Sulfosuccinate EA-disodium; and sulfate esters, such as alkyl ether sulfates, e.g., Sodium Laureth Sulfate, Ammonium Laureth Sulfate, Magnesium Laureth Sulfate, Laureth MIPA Laureth Sulfate, TIPA Laureth Sulfate, Sodium Myreth Sulfate and C12-13 Pa sodium lauryl sulfate, and alkyl sulfates, such as sodium lauryl sulfate, lauryl Ammonium sulfate and TEA lauryl sulfate.

[0191] Cationic surfactants which can be advantageously used include alkylamines, alkyl Imidazoles, ethoxylated amines and quaternary surfactants: RNH2CH2CH2COO - (at pH 7); RNHCH2CH2COO - B + (at pH 12) B + is any cation, e.g., Na +);Esterquats.

[0192] Quaternary surfactants are surfactants that contain at least one aryl group covalently bonded to four alkyl or aryl groups. Contains N atoms, which results in a positive charge regardless of the pH value. Alkyl betaines, Alkylamidopropyl betaine and alkylamidopropyl hydroxysulfane ( The cationic surfactant used is preferably Also preferred are the group of quaternary ammonium compounds, in particular benzyltrialkylammonium chlorides. ammonium or benzyltrialkylammonium bromide, for example benzyldimethylsulfonium chloride Tearyl ammonium, as well as alkyl trialkyl ammonium salts, such as cetearyl chloride. Cetyltrimethylammonium bromide or cetyltrimethylammonium bromide, alkyldichloride Methyl hydroxyethyl ammonium or alkyl dimethyl hydroxyethyl ammonium bromide ammonium, dialkyldimethylammonium chloride or dialkyldimethylammonium bromide ammonium, alkylamidoethyltrimethylammonium ether sulfate, alkylpi pyridinium salts, such as laurylpyridinium chloride or cetylpyridinium chloride, iminopyridinium salts, Dazoline derivatives and compounds of cationic nature, such as amine oxides, e.g. alkyl dimethylamine oxide or alkylaminoethyl dimethylamine oxide Cetyltrimethylammonium salts can be used with particular advantage. do.

[0193] Amphoteric surfactants which can be advantageously used include acyl / dialkylethylene diamines. amines, such as sodium acylamphoacetate, disodium acylamphodipropionate , disodium alkylamphodiacetate, amphohydroxypropyl acylinate sulfonate sodium, disodium acylamphodiacetate and sodium acylamphopropionate; N-alkylamino acids, such as aminopropyl alkylglutamides, alkylaminopropyl propionic acid, sodium alkylimidodipropionate and lauroamphocarboxylate Examples include lysinate.

[0194] Nonionic surfactants which can be advantageously used are: alcohols; alkanols Amides, e.g. cocamide MEA / DEA / MIPA, amine oxides, e.g. cocoa Amidopropylamine oxide; carboxylic acids, ethylene oxide, glycerol, sorbitan or other alcohols; ethers, e.g. Ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / Propoxylated glycerol esters, ethoxylated / propoxylated cholesterol, ethoxylated Ethoxylated / Propoxylated Triglyceride Esters, Ethoxylated / Propoxylated Lanolin, Ethoxylated Oxylated / propoxylated polysiloxane, propoxylated polyoxyethylene (POE) ether Ter- and alkyl polyglycosides, such as lauryl glucoside, decyl glucoside and and coconut glycosides; sucrose esters and ethers; polyglycerol esters, Diglycerol esters, monoglycerol esters; methyl glucose esters, hydro Examples of suitable esters include esters of alkoxy acids.

[0195] Anionic and / or amphoteric surfactants and one or more nonionic surfactants The use of a combination with is also advantageous.

[0196] The surfactant is avenanthramide L or an oat extract containing avenanthramide L. In preparations containing It is possible to exist.

[0197] Within the context of the use according to the invention, avenanthramide L or an endothelial agent containing avenanthramide L is Cosmetics and / or pharmaceutical preparations containing the extract of sorghum are also used as cosmetic or pharmaceutical preparations. Particularly advantageously, one or more emulsifiers are used that are commonly used in the art to prepare The oil-in-water (O / W) emulsifiers can be, for example, polyethoxylated or are polypropoxylated or polyethoxylated and polypropoxylated products, e.g. Fatty alcohol ethoxylate, ethoxylated wool wax alcohol, general formula RO -(-CH2-CH2-O-) n -R', a polyethylene glycol ether of the general formula R- COO-(-CH2-CH2-O-) n -H fatty acid ethoxylates of the general formula R-COO -(-CH2-CH2-O-) n Etherified fatty acid ethoxylates of the general formula R- COO-(-CH2-CH2-O-) n -C(O)-R' esterified fatty acid ethoxylate ester, polyethylene glycol glycerol fatty acid ester, ethoxylated sorbitan ester ter, cholesterol ethoxylate, ethoxylated triglyceride, general formula R-COO- (-CH2-CH2-O-) n -OOH (wherein n is a number from 5 to 30) sorbitol fatty acid esters, polyoxyethylene sorbitol fatty acid esters, -CH2-CH2-O-) n-SO3-H alkyl ether sulfates, general formula RO-( -CH2-CH(CH3)-O-) n -H fatty alcohol propoxylates of the general formula RO-(-CH2-CH(CH3)-O-) n -R' Polypropylene Glycol A Ether, Propoxylated Wool Wax Alcohol, Etherified Fatty Acid Propoxylate R- COO-(-CH2-CH(CH3)-O-) n -R', general formula R-COO-(-CH2 -CH(CH3)-O-) n -C(O)-R' esterified fatty acid propoxylates, General formula R-COO-(-CH2-CH(CH3)-O-) n -H fatty acid propoxylates , Polypropylene glycol glycerol fatty acid ester, Propoxylated sorbitan esther ter, cholesterol propoxylate, propoxylated triglyceride, general formula RO- (-CH2-CH(CH3)-O-) n -CH2-COOH alkyl ether carboxylic acid Acid, general formula RO-(-CH2-CH(CH3)-O-) n -SO3-H alkyl ether Tersulfates (and the acids on which these sulfates are based), general formula ROX n -Y m -H fatty alcohol ethoxylates / propoxylates, general formula ROX n -Y n -R', polypropylene glycol ether of the general formula R-COO-X n -Y n -R'E esterified fatty acid propoxylates, and the general formula R-COO-X n -Y m -H fatty acid ether Advantageously, the compound may be selected from the group comprising the methoxylates / propoxylates.

[0198] According to the invention, the polyethoxylated or polypropoxylated or polyethoxylated Polypropoxylated and polypropoxylated O / W emulsifiers are saturated R and R If it contains ' groups, then it preferably has an HLB value of 11 to 18, more preferably 14.5 to 15.5. The O / W emulsifier is advantageously selected from the group consisting of substances having an HLB value of unsaturated R and and / or R' groups, or when isoalkyl derivatives are present. The preferred HLB value of the emulsifier may also be lower or higher. Ethoxylates are ethoxylated stearyl alcohol, cetyl alcohol and cetyls. It is advantageously selected from the group comprising tearyl alcohol (cetearyl alcohol).

[0199] The following emulsifiers are particularly preferred: polyethylene glycol (13) stearyl ether ( Steareth-13), Polyethylene Glycol (14) Stearyl Ether (Steareth -14), polyethylene glycol (15) stearyl ether (steareth-15), Polyethylene glycol (16) stearyl ether (steareth-16), polyethylene Glycol (17) Stearyl Ether (Steareth-17), Polyethylene Glycol (18) Stearyl ether (steareth-18), polyethylene glycol (19) Stearyl ether (steareth-19), polyethylene glycol (20) stearyl Ether (steareth-20), polyethylene glycol (12) isostearyl ether (Isostearyl ether) Polyethylene glycol (13) isostearyl ether (Isostearyl ether-13), polyethylene glycol (14) isostearyl ether ( Isostearate-14), Polyethylene glycol (15) Isostearyl ether (I Sosteareth-15), Polyethylene Glycol (16) Isostearyl Ether (Iso Steareth-16), Polyethylene Glycol (17) Isostearyl Ether (Isostearyl Ether) Teareth-17), polyethylene glycol (18) isostearyl ether (isostearyl Areth-18), polyethylene glycol (19) isostearyl ether (isostearyl RES-19), Polyethylene Glycol (20) Isostearyl Ether (Isostearyl (ceteth-20), polyethylene glycol (13) cetyl ether (ceteth-13), polyethylene Ethylene glycol (14) Cetyl ether (ceteth-14), polyethylene glycol ( 15) Cetyl ether (ceteth-15), polyethylene glycol (16) Cetyl ether Cetyl ether (ceteth-16), polyethylene glycol (17), cetyl ether (ceteth-17) , Polyethylene glycol (18) cetyl ether (ceteth-18), polyethylene glycol Cole (19) Cetyl Ether (Ceteth-19), Polyethylene Glycol (20) Cetyl Cetyl ether (Ceteth-20), polyethylene glycol (13) isocetyl ether (Iso Isoceteth-13), Polyethylene Glycol (14) Isocetyl Ether (Isoceteth- 14), polyethylene glycol (15) isocetyl ether (isoceteth-15), Triethylene glycol (16) isocetyl ether (isoceteth-16), polyethylene Glycol (17) Isocetyl ether (Isoceteth-17), polyethylene glycol (18) Isocetyl ether (Isoceteth-18), polyethylene glycol (19) Isocetyl Ether (Isoceteth-19), Polyethylene Glycol (20) Isocetyl Ether (Isoceteth-20), Polyethylene Glycol (12) Oleyl Ether (Oleyl (12), polyethylene glycol (13) oleyl ether (oleth-13), poly Ethylene glycol (14) oleyl ether (oleth-14), polyethylene glycol (15) Oleyl ether (oleth-15), polyethylene glycol (12) lauryl Laureth-12, Polyethylene Glycol (12) Isolauryl Ether (Isolaureth-12), Polyethylene Glycol (13) Cetyl Stearyl Ether ( Ceteareth-13, Polyethylene glycol (14) Cetyl stearyl ether (cete Areth-14), polyethylene glycol (15) cetyl stearyl ether (cetearyl -15), polyethylene glycol (16) cetyl stearyl ether (ceteareth- 16), polyethylene glycol (17) cetyl stearyl ether (ceteareth-17 ), polyethylene glycol (18) cetyl stearyl ether (ceteareth-18), Polyethylene glycol (19) cetyl stearyl ether (ceteareth-19) and Polyethylene glycol (20) cetyl stearyl ether (ceteareth-20).

[0200] The fatty acid ethoxylates are also advantageously selected from the following group: polyethylene glycols (20) Stearates, polyethylene glycol (21) Stearates, polyethylene glycol Recall (22) Stearates, polyethylene glycol (23) Stearates, polyethylene Polyethylene glycol (24) stearate, polyethylene glycol (25) stearate , Polyethylene glycol (12) Isostearate, Polyethylene glycol (13) Isostearate, polyethylene glycol (14) Isostearate, polyethylene glycol Recall (15) Isostearate, Polyethylene Glycol (16) Isostearate , Polyethylene glycol (17) Isostearate, Polyethylene glycol (18) Isostearate, polyethylene glycol (19) Isostearate, polyethylene glycol Recall (20) Isostearate, Polyethylene Glycol (21) Isostearate , Polyethylene glycol (22) Isostearate, Polyethylene glycol (23) Isostearate, Polyethylene Glycol (24) Isostearate, Polyethylene Glycol Recall (25) Isostearate, Polyethylene Glycol (12) Oleate, Poly Ethylene glycol (13) oleate, polyethylene glycol (14) oleate, Polyethylene glycol (15) oleate, polyethylene glycol (16) oleate oleate, polyethylene glycol (17) oleate, polyethylene glycol (18) oleate oleate, polyethylene glycol (19) oleate and polyethylene glycol (2 0) OreArt.

[0201] Sodium Laureth-11 Carboxylate is an ethoxylated alkyl ether carboxylic acid or can be advantageously used as its salt. Sodium laureth-14 sulfate is an alkyl Polyethylene glycol (30) can be advantageously used as its diol ether sulfate. Cholesteryl ethers can be advantageously used as ethoxylated cholesterol derivatives. Polyethylene glycol (25) soy sterols have also proven useful. is.

[0202] Polyethylene glycol (60) evening primrose glyceride is an ethoxylated triglyceride. It can be advantageously used as

[0203] Polyethylene glycol glycerol fatty acid esters are also polyethylene glycol (20) Glyceryl laurate, polyethylene glycol (21) Glyceryl laurate , Polyethylene glycol (22) Glyceryl laurate, Polyethylene glycol (2 3) Glyceryl laurate, polyethylene glycol (6) (caprylic acid / capric acid) Glyceryl, Polyethylene Glycol (20) Glyceryl Oleate, Polyethylene Glycol Cole (20) Glyceryl Isostearate and Polyethylene Glycol (18) (O Advantageously, the fatty acids are selected from the group comprising glyceryl oleate / cocoate.

[0204] Sorbitan esters are also available as polyethylene glycol (20) sorbitan monolaurate. Sorbitan, Polyethylene Glycol (20) Sorbitan Monostearate, Polyethylene Glycol Cholesterol (20) sorbitan monoisostearate, polyethylene glycol (20) mono Sorbitan palmitate and polyethylene glycol (20) sorbitan monooleate Advantageously, it is selected from the group comprising:

[0205] As advantageous W / O emulsifiers the following can be used: aliphatic alcohols; saturated and Monoglycerol esters of unsaturated, branched and / or unbranched alkane carboxylic acids ter; saturated and / or unsaturated with a chain length of 8 to 24, especially 12 to 18, C atoms , diglycerol esters of branched and / or unbranched alkane carboxylic acids; 8 to 24 In particular saturated and / or unsaturated, branched and / or unsaturated alkyl chains with a chain length of 12 to 18 C atoms. Monoglycerol ethers of branched or unbranched alcohols; 8-24, especially 12-18 C of saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of Diglycerol ethers; saturated and unsaturated diglycerol ethers with a chain length of 8 to 24, especially 12 to 18, carbon atoms. and / or propylene glycol of unsaturated, branched and / or unbranched alkane carboxylic acids and saturated and unsaturated aryl esters with a chain length of 8 to 24, in particular 12 to 18, C atoms. Sorbitan esters of unsaturated, branched and / or unbranched alkane carboxylic acids .

[0206] Particularly advantageous W / O emulsifiers include glyceryl monostearate, monoisostearate, Glyceryl, Glyceryl Monomyristate, Glyceryl Monooleate, Monostearin Diglyceryl Monostearate, Diglyceryl Monoisostearate, Propylene Glycol Monostearate Cole, propylene glycol monoisostearate, propylene glycol monocaprylate , Propylene Glycol Monolaurate, Sorbitan Monoisostearate, Monolaurate Sorbitan monocaprylate, sorbitan monoisooleate, disodium Sucrose tearic acid, cetyl alcohol, stearyl alcohol, arachidyl alcohol Alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, thymyl alcohol Polyethylene glycol (2) stearyl ether (steareth-2), monolaurate Examples include glyceryl phosphate, glyceryl monocaprate, and glyceryl monocaprylate. can be.

[0207] Within the context of the use according to the invention, avenanthramide L or an endothelial agent containing avenanthramide L is The extract of burdock is also used as a component of perfume compositions for hair and scalp care products. These particular benefits may also provide additional itch relieving properties or anti-allergic properties. Ghee characteristics can be imparted, for example, to perfumed end products. The composition comprises: (a) a sensory effective amount of perfume; (b) an itch-modulating, anti-allergic and and / or a desensitizing amount of a synergistically effective mixture of an anthranilic acid amide and an antidandruff agent, and and (c) optionally including one or more excipients and / or additives. Oat extracts containing avenanthramide L or avenanthramide L have only a weak characteristic odor. They are often or even completely odorless, a property which makes them particularly useful in perfume compositions. This has proven to be particularly advantageous since

[0208] Avenanthramide L or oat extract containing avenanthramide L is a conventional cosmetic product. or dermatological or keratinological preparations, such as pump sprays, aerosol sprays, among others. Creams, shampoos, ointments, tinctures, lotions, nail care products ( For example, it can be easily incorporated into nail polish, nail polish remover, nail balsam, etc. Within this context, a synergistically effective combination of anthranilic acid amide and an antidandruff agent can be Combination with other active compounds is also possible and may be advantageous in some cases. Intravenously contains avenanthramide L or an oat extract containing avenanthramide L. The cosmetic and / or dermatological or keratinological preparations are otherwise conventional in composition. and may be of the skin, hair, etc., within the context of cosmetic care or dermatological or keratinological treatments. It can be used to treat hair and / or nails.

[0209] If the cosmetic or pharmaceutical preparation is a solution or lotion, it can be used Solvents that can be used include: water or aqueous solutions; fatty oils, fats, waxes and other natural Natural and synthetic fatty acids, preferably esters of fatty acids with alcohols having low carbon numbers; For example, isopropanol, propylene glycol or glycerol, or aliphatic alcohols. Esters of alcohols with alkanoic acids having low carbon numbers or with fatty acids; Alcohols, diols or polyols having a high C number and their ethers are preferred. or ethanol, isopropanol, propylene glycol, glycerol, ethylene Glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol Cholesterol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl Monoethyl or monoethyl ether and similar products. Mixtures of the abovementioned solvents are particularly used. In the case of alcoholic solvents, water can be an additional constituent.

[0210] The cosmetic or pharmaceutical preparations may also be in a form suitable for topical application, for example lotions, Aqueous or aqueous alcoholic gels, vesicle dispersions, or simple or complex emulsions (O / W, W / O, O / W / O or W / O / W), liquid, semi-liquid or solid, e.g. For example, milk, cream, gel, cream-gel, paste or stick. The composition may also be formulated into an aerosol, optionally packaged as an aerosol. Such preparations may be applied in the usual manner. It is prepared by:

[0211] To prepare an emulsion, the oily phase can be advantageously selected from the following group of substances: Oils, mineral waxes; fatty oils, fats, waxes and other natural and synthetic fatty bodies, preferably Preferably, fatty acids and alcohols having low carbon numbers, such as isopropanol, propylene Esters with glycols or glycerol, or with fatty alcohols and low carbon numbers esters of alkanoic or fatty acids having the formula: alkyl benzoates; silicone oils; For example, dimethylpolysiloxane, diethylpolysiloxane, diphenylpolysiloxane and mixed forms thereof.

[0212] Advantageously, saturated and / or unsaturated, branched and / or unsaturated alkyl groups with a chain length of 3 to 30 C atoms. and / or linear alkane carboxylic acids with a chain length of 3 to 30 C atoms, saturated and and / or esters with unsaturated, branched and / or linear alcohols, aromatic carboxylic acids , saturated and / or unsaturated, branched and / or Those from the group of esters with linear alcohols can be used. Preferred esters The oils are isopropyl myristate, isopropyl palmitate, and isopropyl stearate. propyl, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-Decyl oleate, isooctyl stearate, isononyl stearate, isonona Isononyl Phosphate, 2-Ethylhexyl Palmitate, 2-Ethylhexyl Laurate, 2-Hexyldecyl tearic acid, 2-octyldodecyl palmitate, oleic acid oleyl erucate, oleyl oleate, erucyl erucate and such esters and synthetic, semi-synthetic and natural mixtures of ethers, such as jojoba oil.

[0213] In addition, the oil phase may be any of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyds, and the like. The group may advantageously be selected from the group comprising saturated or unsaturated, branched or unbranched ethers. or unbranched alcohols, and also fatty acid triglycerides, specifically those with 8 to 24, and especially those with 12 Saturated and / or unsaturated, branched and / or unbranched with a chain length of ~18 C atoms Contains triglycerol esters of alkane carboxylic acids. Fatty acid triglycerides are synthetic , semi-synthetic and natural oils, such as olive oil, sunflower oil, soybean oil, peanut oil, natto oil, Advantageously selected from the group consisting of seed oil, almond oil, palm oil, coconut oil, palm kernel oil, etc. Any mixture of such oil and wax components may also be used to advantage. In some cases, a wax, e.g., pulp, may be used as the only lipid component of the oil phase. It is also advantageous to use cetyl methacrylate. Advantageously, the oil phase is 2-ethylhexyl Sostearate, Octyldodecanol, Isotridecyl Isononanoate, Isoeico San, 2-ethylhexyl coconut oil fatty acid, C12-15 alkyl benzoate, caprylic acid Selected from the group including capric triglyceride and dicaprylyl ether. ~15 Mixture of alkyl benzoate and 2-ethylhexyl isostearate, C12~15 Mixtures of alkyl benzoates and isotridecyl isononanoate and C12-15 benzoates Alkyl acetate, 2-ethylhexyl isostearate and isotridecyl isononanoate Particularly advantageous are mixtures of paraffin oil, squalane and squalene. The oil phase can also advantageously be used as a cyclic or linear silicone oil. It may contain or consist entirely of such oils, but may also contain other An oil phase component is preferably used in addition to silicone oil. Cyclomethicone (e.g., Decamethylcyclopentasiloxane can be advantageously used as a silicone oil. However, other silicone oils can also be used to advantage, including, for example, unsilicon oils. Decamethylcyclotrisiloxane, polydimethylsiloxane and poly(methylphenyl Siloxane) Cyclomethicone and isotridecyl isononanoate and cyclomethicone Mixtures of lomethicone and 2-ethylhexyl isostearate are also particularly advantageous.

[0214] Contains avenanthramide L or an oat extract containing avenanthramide L, and is an emulsion The aqueous phase of the preparation is preferably an alcohol, diol or polyol having a low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol Cole, glycerol, ethylene glycol, ethylene glycol monoethyl or mono Butyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether diethylene glycol monomethyl or monoethyl ether and similar products, Also alcohols with low carbon numbers, such as ethanol, isopropanol, 1, 2-propanediol and glycerol, and in particular one or more thickeners, are advantageously used. The thickening agent may include silicon dioxide, aluminum silicate, polysaccharides and derivatives thereof. Groups including conductors, such as hyaluronic acid, xanthan gum, hydroxypropyl methylcellulose particularly preferably from the group comprising the polyacrylates, preferably the so-called Carbopols; Polyacrylates from the group including, for example, Carbopol types 980, 981, 1382, 2 984 and 5984, each of which may be advantageously selected by itself or in combination. It is possible.

[0215] High content of treatment substances is used in a wide range of applications for topical, preventive or cosmetic treatment of the skin. In a preparation containing oat extract containing venanthramide L or avenanthramide L, According to a preferred variant, the composition is administered to one or more animals and / or or vegetable processed fats and oils, such as olive oil, sunflower oil, refined soybean oil, Palm oil, sesame oil, rapeseed oil, almond oil, borage oil, evening primrose oil, coconut oil, Butter, jojoba oil, sperm whale oil, beef tallow, beef foot oil and lard, and optionally and other treating constituents, such as C8 to C30 fatty alcohols. The fatty alcohols used can be saturated or unsaturated and straight-chain or branched. Examples include decanol, decenol, octanol, octenol, and dodecanol. , dodecenol, octadienol, decadienol, dodecadienol, oleyl alkanol Cole, ricinoleyl alcohol, erucic alcohol, stearyl alcohol, isostearyl alcohol Allyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, Laxil alcohol, Capryl alcohol, Capric alcohol, Linoleyl alcohol linoleyl alcohol and behenyl alcohol, as well as their guerbet alcohols This list may be expanded, if desired, to include other structurally and chemically related The fatty alcohols can be expanded to include alcohols. The fatty alcohols are preferably naturally occurring fatty acids. They are derived from fatty acids and are usually prepared by reduction from the corresponding esters of fatty acids. Fatty alcohol fractions formed by reduction from fats and fatty oils, e.g. beef tallow, peanut canola oil, rapeseed oil, cottonseed oil, soybean oil, sunflower oil, palm kernel oil, linseed oil, corn Also used are canola oil, castor oil, rapeseed oil, sesame oil, cocoa butter and cocoa fat. can be done.

[0216] Treatments which may be preferably combined with the composition or oat extract according to the invention Other examples of substances that may be mentioned include: ceramides, N-acylsphingosines, etc. (fatty acid amides of sphingosine) or synthetic analogues of such lipids ( These are so-called pseudo-ceramides, which significantly improve the water-retaining capacity of the stratum corneum; Lecithins, such as soy lecithin, egg lecithin and cephalin; Vaseline, Paraffin and silicone oils, the latter among others dialkyl- and alkylaryl-siloxanes. For example, dimethylpolysiloxane and methylphenylpolysiloxane, and These include alkoxylated and quaternized derivatives.

[0217] Hydrolyzed animal and / or plant proteins may also be used in the compositions or extracts according to the invention. These can be advantageously added to preparations containing barley extract. Advantageous examples in this connection are: Especially elastin, collagen, keratin, milk protein, soy protein, oenocyte protein Proteins, pea proteins, almond proteins and wheat protein fractions or corresponding Hydrolyzed proteins that are capable of producing fatty acids, as well as their condensation products with fatty acids, and further quaternized hydrolyzed proteins. Examples of suitable proteins include vegetable proteins, and the use of hydrolyzed vegetable proteins is preferred.

[0218] Cosmetics containing avenanthramide L or oat extract containing avenanthramide L Alternatively, the pharmaceutical preparation may also comprise a cosmetically or pharma- ceutically acceptable carrier, e.g., ...utical preparation, e.g., a cosmetically or pharma- ceutical These may include, but are not limited to, one of the following commonly used in the field of medicine: (Lactose, glucose, sucrose, sorbitol, mannitol, starch, alginate, etc.) Cassia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline Cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, Methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate Cosmetics or pharmaceutical preparations may also contain, in addition to the above components, lubricants, It may contain wetting agents, sweetening agents, flavoring agents, emulsifying agents, suspending agents, preserving agents, and the like. Pharmaceutically acceptable carriers and formulations are described in Remington's Pharmaceuticals and al Sciences (19th ed., 1995).

[0219] In a preferred variant, the food, nutritional supplement, cosmetic, pharmaceutical or veterinary preparation is Avenanthramide L or Avenanthramide L per total weight or final composition of the product 0.0001 to 10% by weight, preferably 0.0005 to 5% by weight of an oat extract containing More preferably, the content is 0.001 to 1% by weight.

[0220] For use, a cosmetic or pharmaceutical preparation containing avenanthramide L or avenanthramide L is The preparations containing ensulamide L are prepared in sufficient quantities and in the manner customary for cosmetics or pharmaceuticals. The composition is applied to the skin, hair and / or nails in such a manner.

[0221] Avenanthrene due to its significant effect of inhibiting the neurokinin-1 receptor NK1R. Oat extracts containing avenanthramide L or avenanthramide L inhibit the neurokinin-1 receptor N Suitable as a K1R antagonist.

[0222] Thus, according to another aspect, the present invention provides a neurokinin-1 receptor NK1R antagonist. Avenanthramide L or an oat extract containing avenanthramide L as a steroid .

[0223] Finally, the present invention provides a method for preparing avenalumic acid and / or avenanthramide L. A method for (a) Triethyl phosphite (1) is reacted with methyl 4-bromocrotonate (2) to obtain methyl Stearyl esters forming ethyl(2E)-4-(diethylphosphoryl)but-2-enoate (3) UP; (b) In the HWE reaction, methyl(2E)-4-(diethylphosphoryl)but-2-ene The methyl ester (2E, 4E) is obtained by reacting the methyl ester (3) with 4-formylphenyl acetate (4). -5-(4-hydroxyphenyl)penta-2,4-dienoate (5) UP; (c) Deprotection of avenalmic acid methyl ester (5) using sodium hydroxide solution. 3. Protecting the β-amino acid from the α-amino acid to produce avenalmic acid (AvnAc); and (d) Using a coupling reagent, avenalmic acid (Av n Ac) with 2-amino-5-hydroxybenzoic acid (6) to give avenanthramine. Step to generate Avn L The present invention relates to a method comprising the steps of:

[0224] For the synthesis of avenalmic acid (Avn Ac), Li Y. et al., Food Chem. The published procedure from Journal of Physics, Vol. 158, pp. 41-47, 2014, was used with some modifications. Starting from triethyl phosphite (1) and methyl 4-bromocrotonate (2), methyl (2E)-4-(diethylphosphoryl)but-2-enoate (3) was approximately The product was formed in 80% yield.

[0225] In the HWE reaction with 4-formylphenyl acetate (4), methyl (2E)-4-(diphenyl)acetate was Ethyl phosphoryl but-2-enoate (3) was used directly.

[0226] In a preferred variant, in contrast to the known procedure from Li Y. et al., the method according to the invention The method step (b) in the process is carried out at a temperature of -78°C → 0°C, preferably at a temperature of -58°C → 0°C. Methyl (2E, 4E)-5-(4-hydroxyethyl) Diphenyl)penta-2,4-dienoate (5; avenalmic acid methyl ester) They are produced in good yields and excellent purity, which can be obtained by simple trituration.

[0227] In comparison with known syntheses, the intermediate product (5) can be advantageously purified by precipitation due to its polarity. It is possible.

[0228] Starting from avenalmic acid methyl ester (5), 1M sodium hydroxide solution was used to synthesize The final deprotection step was carried out using 1,2-dichlorophenyl ether (1,2-dichlorophenyl)-2,4-tetrahydrofuran ... Ac) in quantitative yield and excellent purity.

[0229] In comparison with known syntheses, this synthetic step can be carried out under mild conditions.

[0230] To synthesize avenanthramide L (Avn L), it was surprisingly possible to use a coupling reagent ( Hydroxybenzotriazole (HOBt) and 1-ethyl-3-(3-dimethylamine) (EDC) or 1-cyano(Ccano)-2-ethoxy -2-Oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexa The pure aryl ester was prepared without any protecting groups using trifluorophosphate (COMU). Benalmic acid (Avn Ac) was reacted with 2-amino-5-hydroxybenzoic acid (6) to give I did. [ka]

[0231] The synthesis of the present invention is described in Miyagawa, H. et al., Bioscience, Biotechn ology, Biochemistry, 1995, Vol. 59(12), 2305-23 Compared to the synthesis previously reported on page 6, the number of steps required was reduced by three. Can.

[0232] The use of coupling reagents and unprotected starting materials surprisingly avoids the use of hazardous compounds, e.g. For example, faster, cheaper, and more environmentally friendly methods that avoid thionyl chloride or oxalyl chloride are available. The purification of avenanthramide L was achieved by aqueous separation followed by crystallization. This can be done by HPLC, producing good purity, or by using preparative HPLC afterwards. This resulted in superior purity and yield, as demonstrated in Example 8 below. Done.

[0233] While the invention has been specifically shown and described with reference to preferred embodiments thereof, Various changes in form and detail may be made without departing from the spirit and scope. Moreover, the present invention is not limited to the above-mentioned specific examples. Any combination of the above-described elements in all possible variations thereof is intended to be illustrative and not restrictive. do.

[0234] The present invention will now be described in detail with reference to the following examples, which are merely illustrative of the present invention. The invention is not limited by or to the following examples, which are merely illustrative of the invention. This is not to be the case. EXAMPLES

[0235] Examples of the present invention are described below. However, it is understood that the present invention is not limited to the described examples. should not be interpreted as such. EXAMPLES

[0236] NK1 receptor inhibition experiment

[0237] Avenanthramide L versus dihydroavenanthramide D and structurally related avenans. The inhibitory activities of ramides A and D were evaluated in radioligand binding assays.

[0238] The methods utilized in this study were based on scientific literature to maximize reliability and reproducibility. The reference compound L-703,606 was run as an integral part of each experiment. The results obtained were validated. An assay was performed.

[0239] method: Tachykinin NK1 Source: Human recombinant CHO cells Vehicle: H2O Incubation time / temperature: 90 minutes at 4°C Incubation buffer: 20 mM HEPES, pH 7.4, 1mM MnCl2 0.1% BSA Kd: 2.10nM Ligand: 0.80 nM [3H] substance P Non-specific ligand: 10.0 μM L-703,606 oxalate (CAS144425- 84-3) Specific binding: 90% Significance criteria: ≥50% maximal stimulation or inhibition B max : 1.70 pmol / mg protein

[0240] References: Patacchini R., Maggi CA, Tachykinin rece ptors and receptor subtypes, Archives int ernationales de Pharmacodynamie et de Th erapie, 1995, vol. 329: 161-184

[0241] [Table 2]

[0242] Surprisingly, it has one more double bond (n=2) than avenanthramide A (n=1). Avenanthramide L, which is twice as active at the test concentration of 100 ppm (42% vs. Avenanthramide L also surprisingly inhibited the NK1 receptor antagonists known from the literature. Avenanthramide C is more active than the avenant agonist dihydroavenanthramide D. It has approximately twice the activity of sulamide L, but is extremely unstable, whereas As can be seen from 2, avenanthramide L is significantly less degradable. EXAMPLES

[0243] Stability study of different avenanthramides in solution

[0244] Avenanthramide alone and in admixture in aqueous ethanol solution under exposure to oxygen and temperature Pure avenanthramides, both dissolved as a mixture, were evaluated.

[0245] The avenantharmide mixture used was DragoC alm® (Symrise; INCI name: aqua, glycerin, Avena Sativa seed extract) or DragoCalm® SP (Symris e;INCI Name: aqua, glycerin, pentylene glycol, Avena Sati va seed extract).

[0246] The liquid was exposed to 5 bar oxygen at 70°C for 24 hours using an Oxipress device. or stored in a heating cabinet at 40° C. for 2 and 4 weeks.

[0247] Before and after treatment, the content of Avns was determined by HPLC and the color was measured colorimetrically ( Hach Lange Lico690 device).

[0248] Colors can be determined using the CIELAB color model, which is based on the opponent color system. ELAB is based on nonlinearly compressed coordinates, with values ​​on three axes: L*, a*, and b*. The color is indicated by the dimension , the lightness by the dimension L, and the red / green and yellow / blue opponent colors The dimensions of the L* are indicated by a* and b*. The L* axis ranges from black (0) to white (100). The a* axis goes from green (-a) to red (+a), and the b* axis goes from blue (-b) to yellow (+ b) It spreads to

[0249] The difference between the two colors, ΔE, can be calculated using the following equation:

number

[0250] The difference ΔE of 0.5 to 1 can be visually observed by an experienced evaluator with the naked eye. Differences 2 to 4 can be visually observed even by a non-skilled evaluator.

[0251] [Table 3]

[0252] The best NK1 receptor inhibitor, Avn C, is also the most unstable, whereas Avn The results clearly show that Avn A is stable but has a significantly lower activity. It is half as effective as Avn C, but significantly more stable.

[0253] The avenanthramide mixture supports these results. Avenanthramide C is a cytotoxic agent that is highly toxic to humans due to exposure to oxygen. After 24 hours, the decomposition was complete, but the Avn L content decreased by only 13%. Avenanthramide A has low biological activity but is stable under these conditions.

[0254] [Table 4]

[0255] The least effective NK1R inhibitor, Avn A, was the most stable (2 and 4 at 40°C). after 2 weeks), followed by Avn L (no degradation after 2 weeks, 9% after 4 weeks). The results clearly show that Avn C is the most potent NK1R inhibitor. It is the least stable when exposed to high temperatures, with 20% decomposition after 2 weeks and Later it shows 50% decomposition. EXAMPLES

[0256] Effect of avenanthramide on the expression of heat shock proteins in human keratinocytes for

[0257] The EpiLife® containing HKGS kit (Gibco) was used according to the manufacturer's instructions. Human neonatal epidermal keratinosa was cultured in 100% ethanol at 37°C with 5% CO2 in 100% ethanol medium (Gibco). We cultured nHEK cells.

[0258] Test compounds dissolved in DMSO and test compounds dissolved in DMSO alone as vehicle controls Cells were treated with test compounds for 24 hours. Quantitative real-time PCR with vehicle control treatment Comparisons were used to measure genomic target expression levels in treated cells.

[0259] Use Qiagen's RNeasy® Mini Kit to isolate RNA. Eppendorf's μCuvetteG1.0 and BioPhotom Total RNA concentration was determined by measuring absorbance at 260 nm using an eter. Purity control values, e.g., E260 / 280 and E260 / 230, were calculated simultaneously. Using the high-performance RNA-to-cDNA kit from Plied Biosystems Reverse transcription was performed according to the manufacturer's instructions. Samples were PCR-therm Processed with ocycler.

[0260] For rapid real-time PCR, cDNA was diluted with RNase-free water and applied TaqMan Fast Universal Pro CR Master Mix was used. Quantitative real-time PCR using the tepOnePlus fast real-time PCR instrument R was used. StepOne software and -ΔΔct Method (endogenous control HTRP Analysis was performed using 1 expression (normalized to 1 expression).

[0261] For upregulation, an RQ value of ≧2.0 is considered relevant.

[0262] [Table 5]

[0263] Avenanthramide L inhibits the small heat shock protein HSPB2 (HS p27) and CRYAB (=αB-crystallin), but not the large heat shock pathway. The results showed that the proteins HSP90AA1 and HSP90AB1 had no effect. do.

[0264] Unlike avenanthramide L, avenanthramide A showed no significant difference at the same test concentration of 100 μM. When tested, they did not result in relevant upregulation of small HSPs or were clearly ineffective. Only in this way can the upregulation of HSPB2 gene expression be achieved. (RQ value of 5.0 vs. 1.9). EXAMPLES

[0265] Keratinocyte gene expression Human neonatal epidermal keratinocytes (nHEK) were cultured and treated with the test compound for 24 hours. Then, another custom gene array with different genes was used to identify the genes that were identified as described in Example 3. Rapid real-time PCR was performed as described above.

[0266] [Table 6]

[0267] Avenanthramide L at 100 μM upregulates BLVRB and CD44 On the other hand, the results show that avenanthramide A has no effect at the same tested concentrations. . EXAMPLES

[0268] Radical scavenging activity (ABTS assay)

[0269] With the help of ABTS assay, the antioxidant capacity of Avn L and Avn A was evaluated. Compared.

[0270] Using potassium persulfate, 2,2'-azino-bis-(3-ethylbenzothiazoline -6-sulfonic acid (ABTS) to blue-green radical cation ABTS ●+ Convert to [6] The radical cation was reduced via the addition of -paradol and α-tocopherol. A color change was observed as determined photometrically by absorbance at 734 nm. The inhibition of radical formation in a substance is calculated by the following formula:

number

[0271] The inhibition of radical formation [%] in a series of dilutions of the tested samples was used to determine the IC50. The concentration at which radical formation is inhibited by 50% was calculated, and the results are shown in Table 7.

[0272] [Table 7]

[0273] Avn L has almost the same antioxidant activity as Avn A at almost the same concentrations. The results clearly show this. EXAMPLES

[0274] Cellular antioxidant activity (DCF-DA assay)

[0275] Primary human dermal fibroblasts were cultured in 96-well microtiter plates at 0.5x1 0 4 The cells were seeded at a concentration of 1000 cells / well. The cells were cultured in DME enriched with 10% fetal calf serum. The incubation was performed in 100 mM NaCl at 37°C and 5% CO2. Confluence was determined by incubation with the test substances. The incubation time was expected to be around 70%. After 24 h of incubation, the cells were stained with DAPI (1:1000). Add 100 μL of H2DCF-DA solution (10 μM) to all samples (background (except for the control) and incubated for 1 hour to convert H2DCF-DA to cellular esterase The resulting H2DCF was trapped inside the cells. After incubation, cells were washed and challenged with pro-oxidant (1 mM, 1 h) The generated fluorescence is expressed as λ ex 504 nm; λ em Read at 524 nm. ROS (reactive Increased levels of oxidative stress (O2) resulted in increased fluorescence.

[0276] The inhibition of oxidation in the presence of the test substance was calculated according to the following equation:

number

[0277] The abbreviations have the following meanings: RFU test substances: Relative fluorescence units for wells with test substance and cells RFU control: Relative fluorescence units for wells with cells but no test substance RFU without cells: Relative fluorescence units for wells without test substance and without cells (blank)

[0278] [Table 8]

[0279] In cell lines, avenanthramide L inhibited avenanthramide at the same test concentration of 500 μM. The results clearly show that it exhibits higher antioxidant activity than sulamide A. EXAMPLES

[0280] NK1 receptor inhibition experiments for synergistic effects

[0281] In a separate experiment, to examine potential synergistic effects, radiation therapy as described in Example 1 was performed. In the ligand binding assay, the combination of avenanthramide L with another avenanthramide The inhibitory activity was evaluated in comparison with the inhibitory activity of either substance alone.

[0282] In the context of this text, synergy is the action of more than just the additive effects of compounds that exhibit synergistic effects. This should be understood to mean an increasing effect. smetics & toiletries, 2000, Vol. 115(No. 11), No. 59-62 , and F. C. Kull et al., Applied Microbiology, 1961, 9, pp. 538-541, this is recorded by the Synergy Index (SI) value. Substance combinations in which both components show a synergistic increase in action, as well as Only one component exhibits synergistic effects, while the other components act merely as boosters. Combinations of substances that only act together fall within the given definition of synergistic action.

[0283] The combination of Avn L and Avn A inhibits the tachykinin NK1 receptor. The synergy index (SI) value by ll was calculated as follows: Kull's equation: SI=C×l / L+C×a / A C = Combinatorial inhibition L = inhibition of Avn L A=Avn A inhibition l = proportionality factor for Avn L in the mixture = 0.2 a = proportionality factor of Avn A in the mixture = 0.8

[0284] [Table 9]

[0285] Experiments again confirm the superior activity of Avn L against Avn A. .

[0286] Evidence of synergistic action is provided by SI values ​​> 1, which indicates that the combined inhibition of the two Avns This is because it is stronger than the proportional contributions of each of the individual factors when they are taken individually.

[0287] The SI of 2.546 indicates a synergistically increased inhibitory effect of Avn L and Avn A. It is clear that synergistic combinations of active compounds are more effective than combinations of active compounds, especially those with lower overall activity. This has the advantage that it is needed to achieve a certain effect. EXAMPLES

[0288] Extraction of unmilled naked oat (Avena nuda) kernels using different extraction agents. extraction

[0289] 100 g of naked oat kernels (purchased from Bohlenser Muehle, Germany) were Oliver) was added to 300g of the extractant given in the table below (w / w). The mixture was cooled to room temperature and the kernels were centrifuged. The extracted grains were separated from the extraction liquid by filtration. The mixture was extracted again at 55°C for 2 hours and the extract was separated from the kernels as described above. The two extracts were combined and the extraction solvent was removed under vacuum using an evaporator. The extract was removed and the resulting dry extract was weighed to determine the extraction yield. by HPLC at 330 nm on an ODS-AQ column (YMC) using a formic acid gradient; Avns were quantified in the dried extracts.

[0290] [Table 10] EXAMPLES

[0291] Formulation examples

[0292] In Formulation Examples 1 to 11, the following two perfume oils PFO1 and PFO2 were used as perfumes ( DPG = dipropylene glycol) was used.

[0293] [Table 11]

[0294] [Table 12]

[0295] [Table 13-1] [Table 13-2] [Table 13-3] [Table 13-4] [Table 13-5] [Table 13-6] [Table 13-7] [Table 13-8] [Table 13-9] [Table 13-10] [Table 13-11] [Table 13-12] [Table 13-13]

[0296] [Table 14]

[0297] [Table 15]

[0298] [Table 16]

[0299] [Table 17]

[0300] [Table 18]

[0301] [Table 19] EXAMPLES

[0302] Synthesis of avenanthramide L

[0303] Step 1: Synthesis of methyl (2E)-4-(diethoxyphosphoryl)but-2-enoate Growth [ka]

[0304] Testing Procedure: Methyl 4-bromocrotonate (15.57 ml, 132.4 mmol, 1.0 equiv.) and triethyl phosphite (22.70 mL, 132.4 mmol, 1.0 equiv.) were added to a round-bottom flask. The RM was then cooled to room temperature. C analysis (Hex:EtOAc, 1:1) confirmed consumption of starting material and formation of desired product. I acknowledged.

[0305] Post-processing: No additional workup was performed.

[0306] purification: The reaction mixture was poured onto silica and the column was eluted with Hex:EtOAc (20-100%). The pure product was concentrated to dryness to give 21.7 g (68% yield). ) to produce methyl (2E)-4-(diethoxyphosphoryl)but-2-enoate (3) did.

[0307] Figure 1 shows (3). 1 H NMR spectrum, CDCl3, 300 MHz. 6.98 - 6.85 (m, 1H), 5.99 (d, J = 15 Hz, 1H), 4.20 - 4.10 (m, 8 Hz, 4H), 3.77 (s, 3H), 2.77 (dd, J = 24 Hz, 8 Hz, 2H), 1.35 (t, J = 8 Hz, 3H).

[0308] Step 2: Methyl(2E,4E)-5-(4-hydroxyphenyl)penta-2,4- Synthesis of dienoates [ka]

[0309] Testing Procedure: Methyl (2E)-4-(diethoxyphosphoryl)but-2-enoate (5.7 g, 2 A solution of 4.17 mmol, 1.0 equiv.) in dry THF was placed in a low-temperature reactor under an argon atmosphere. NaH (4.021 g, 100.57 mmol, 4.16 equiv.) in dry THF The mixture was stirred at -50°C for 0.5 h and then cooled to -50°C for 0.5 h. Then 4-formylphenyl acetate (3.294 g, 20.06 mmol, 0.83 equiv.) A solution of in dry THF was added dropwise. The reaction temperature was raised to 0° C. and the mixture was stirred for another 2 hours. Stirred.

[0310] Post-processing: The reaction mixture was quenched with saturated NH4Cl solution, followed by extraction with EtOAc. The organic layers were combined, dried over Na2SO4 and concentrated to dryness.

[0311] purification: The crude product (1 vol) was triturated with MeOH (10 vol). A precipitate formed and was filtered. - Filter through a separatory funnel to give avenalmic acid methyl ester (3.17 g, 77%) (5). did.

[0312] Figure 2 shows (5). 1 H NMR spectrum shows CDCl3, 300 MHz. 7.82 - 7.41 (m , 4H), 6.99 - 6.72 (m, 3H), 5.97 (d, J = 15 Hz, 1H), 5.10 (br s, 1H), 3.80 (s, 3 H).

[0313] Step 3: (2E,4E)-5-(4-hydroxyphenyl)penta-2,4-diene Acid synthesis [ka]

[0314] Testing Procedure: Methyl (2E,4E)-5-(4-hydroxyphenyl)penta-2,4-dienoate Dissolve 4.14 g, 20.27 mmol, 1.0 equiv in MeOH (165.6 g, 40. 0 vol) and then 1M NaOH (165.6 g, 40.0 vol) was added. The reaction was stirred overnight at room temperature.

[0315] Post-processing: The MeOH was evaporated. The crude product was acidified with 1M HCl and extracted using EtOAc. The organic layers were combined, dried over Na2SO4, concentrated to dryness, and purified by avenal amines. Acid was produced (3.8 g, 99% Avn Ac).

[0316] Figure 3 shows the structure of avenalmic acid (Avn Ac). 1 H NMR spectrum of DM SO-d6, 400 MHz. 12.10 (s, 1H), 9.81 (s, 1H), 7.43 - 7.36 (m, 2H), 7.31 (dd, J =1 5.2, 10.2 Hz, 1H), 6.95 (d, J = 15.6 Hz, 1H), 6.88 (dd, J = 15.5, 10.3 Hz, 1H), 6.80 - 6.74 (m, 2H), 5.90 (d, J = 15.1 Hz, 1H), 1.23 (s, 1H).

[0317] Figure 4 shows the structure of avenalmic acid (Avn Ac). 13 C NMR spectrum of DM SO-d6, 101 MHz. 167.62, 158.42, 144.92, 140.16, 128.77, 126.98, 123.19, 120.06, 115.60, 40.09, 40.03, 39.82, 39.62, 39.41, 39.20, 38.99, 38.78.

[0318] Figure 5 shows the results for Gemini-NX3μMC18 (4.6×50mm), column gradient flow rate 0. 5 ml / min, 0 min → 2 min, 95% water / 5% MeCN; 2 min → 9.5 min, linear gradient Use 95-20% water and 5-80% MeCN, then hold for 1 minute, each Avenal for m / z-1=188.8 with 0.1% solvent modifier formic acid 1 shows the LCMS spectrum of methyl 2,4-dihydropyridine.

[0319] Step 4: 5-Hydroxy-2-[(2E,4E)-5-(4-hydroxyphenyl) Synthesis of penta-2,4-dienamido]benzoic acid [ka]

[0320] Test Procedure 1: (2E,4E)-5-(4-hydroxyphenyl)penta-2,4-dienoic acid (0.1 g, 0.53mmol, 1.0eq), COMU(0.27g, 0.63mmol, 1. 1 equiv.) and DIPEA (0.41 g, 3.17 mmol, 6.0 equiv.) in DMF (5 The reaction mixture was stirred for 10 minutes and then added 2-amino-5-hydroxybenzoate. Benzoic acid (0.08 g, 0.53 mmol, 1.0 equiv) was added and the reaction mixture was allowed to stand at room temperature overnight. The mixture was stirred at rt. LCMS analysis confirmed consumption of starting material and formation of a new product.

[0321] Or alternatively:

[0322] Testing Procedure 2 (Preferred): (2E,4E)-5-(4-hydroxyphenyl)penta-2,4-dienoic acid (1.5 5g, 8.15mmol, 1.0eq), HOBt(1.21g, 8.96mmol, 1 0.1 equiv.), EDC HCl (1.71 g, 8.96 mmol, 1.1 equiv.) and DI PEA (7.11 ml, 40.75 mmol, 5.0 equiv.) in DMF (38.75 ml) The reaction mixture was stirred for 10 minutes and then dissolved in 2-amino-5-hydroxybenzoic acid. (1.24 g, 8.15 mmol, 1.0 equiv) was added. The reaction mixture was stirred overnight at room temperature. LCMS analysis confirmed consumption of starting material and formation of a new product.

[0323] Post-processing: EtOAc was added to the reaction mixture and the mixture was washed with 1M HCL (5×100 ml). The organic layer was dried over Na2SO4 and concentrated to dryness.

[0324] purification: Via recrystallization (water / methanol) or preparative HPLC Gemini-NX5μ On a M C18 (250 × 21.2 mm), a column gradient flow rate of 20 ml / min was used, with 0. The crude product was purified using water and acetonitrile with 1% formic acid as a modifier. The mixture was purified as follows: 67% water, 0 min → 15 min, 50% water; 15 min → 16 min, 5% water; hold for 4 min and produced 250 mg (12%) of avenanthramide L.

[0325] Figure 6 shows the structure of avenanthramide L. 1 H NMR spectrum, DMSO-d6, 400 MHz . 10.92 (s, 0H), 9.78 (s, 1H), 9.57 (s, 1H), 8.35 (d, J = 9.0 Hz, 1H), 7.44 - 7. 38 (m, 2H), 7.37 (d, J = 2.9 Hz, 1H), 7.31 (ddd, J = 14.9, 7.3, 3.0 Hz, 1H), 7.0 1(dd, J = 9.0, 3.0 Hz, 1H), 6.94 (d, J = 7.3 Hz, 1H), 6.94 (d, J = 3.2 Hz, 1H), 6.80 - 6.75 (m, 2H), 6.20 (d, J = 14.8 Hz, 1H).

[0326] Figure 7 shows the structure of avenanthramide L. 13 C NMR spectrum, DMSO-d6, 101 M Hz. 169.18, 163.32, 158.25, 152.35, 141.45, 139.32, 132.87, 128.63,127.20, 123.7 0, 123.40, 121.99, 120.78, 118.13, 116.43, 115.59, 40.09, 40.04, 39.83, 39.62, 3 9.42, 39.21,39.00, 38.79, 0.00.

[0327] Figure 8 shows the LCMS spectrum of avenanthramide L (m / z-1 = 324. 01).

Claims

1. Avenanthramide L or NK1R antagonists or the use of an oat extract containing avenanthramide L.

2. To induce expression of small heat shock proteins (sHSPs) or expression of CD44 -Avenanthramide L or an oat extract containing avenanthramide L for inducing Use of.

3. Small heat shock proteins (sHSPs) include sHSP27 (HSPB1, HSPB2, HSP3, HSP4, HSP5, HSP6, HSP7, HSP8, HSP9, HSP10, HSP11, HSP12, HSP13, HSP14, HSP15, HSP16, HSP17, HSP18, HSP19, HSP20, HSP21, HSP22, HSP23, HSP SPB3) and αB-crystallin (CRYAB / HSPB5). The use according to claim 2.

4. Avenanthramide L as an antioxidant or for inducing the expression of BLVRB or the use of an oat extract containing avenanthramide L.

5. as a cosmetic product for skin care, hair care or nail care and / or Sensitive skin, hair or nails, skin irritation, skin redness, wheals, pruritus (itching), skin aging, formation of wrinkles, loss of skin volume, loss of skin elasticity, pigmentation spots, pigmentation abnormalities, dry skin, i.e.

2. The method of claim 1 for use in the prevention and / or treatment of dry skin in need of moisturization.

5. Avenanthramide L or an enzyme containing avenanthramide L according to any one of claims 1 to 4. Use of tapir extract.

6. Avenanthramide according to any one of claims 1 to 4 for use as a medicine. Oat extract containing avenanthramide L or avenanthramide L.

7. Skin or keratinopathy, especially barrier-related, inflammatory, immunoallergic, atherosclerotic Prevention and treatment of skin or keratin diseases having a keratinogenic, dry or hyperproliferative component Avenanthramide L or avenanthramide L according to claim 6 for use in the treatment and / or management of Oat extract containing venanthramide L.

8. Skin diseases include eczema, psoriasis, seborrhea, dermatitis, erythema, pruritus (itching), otitis, xerosis, inflammation rash, irritation, fibrosis, lichen planus, pityriasis rosea, tinea versicolor, autoimmune blistering disease, urticaria skin reactions, angiodermal and allergic skin reactions, and wound healing. The avenanthramide L or ember containing avenanthramide L according to claim 7 is selected from the group consisting of Extract.

9. A method according to claim 1 for preparing a food, a dietary supplement, a cosmetic, a pharmaceutical or a veterinary preparation.

5. The avenanthramide L or avenanthramide extract according to any one of claims 1 to 4. Use of DoL.

10. The oat extract is derived from a plant of the Avena genus, in particular the oat species Avena sati and / or the extract is an extract derived from Avena va or Avena nuda.

10. The method according to claim 1, which is an alcoholic or aqueous acetone extract. Use of.

11. Avenanthramide L or an oat extract containing avenanthramide L is At least one naturally occurring analogue of avenanthramide other than avenanthramide L, particularly avenanthramide L. From the group consisting of A, B, C, G, H, K and R, and / or mixtures thereof In combination with at least one selected naturally occurring analog avenanthramide. , and / or avenanthramide L or an oat extract containing avenanthramide L The product is used in combination with at least one non-naturally occurring analog avenanthramide.

11. The use according to any one of claims 1 to 10.

12. Avenanthramide L or an oat extract containing avenanthramide L, - anti-inflammatory, antibacterial or antifungal substances, and / or - Substances that have a redness-relieving or itching-relieving effect, and / or - emollients, and / or - moisturizing and conditioning agents, and / or - Cooling agent The use according to any one of claims 1 to 11, used in combination with

13. Avenanthramide L or an oat extract containing avenanthramide L has antioxidant and antibacterial properties. Selected from the group consisting of preservatives, (metal) chelating agents, penetration enhancers and / or mixtures thereof. The use according to any one of claims 1 to 12, in combination with an excipient of choice. For.

14. Cosmetic or pharmaceutical preparations are administered topically, in particular in the form of solutions, tinctures, lotions, gels 5 or 6, which is used in the form of a cream, ointment, spray or shampoo.

14. The use according to any one of claims 13 to 13.

15. The food, dietary supplement, cosmetic, pharmaceutical or veterinary preparation comprises avenanthramide L or The oat extract containing avenanthramide L was added in an amount of 0.0001 to 0.001 g / l based on the total weight of the preparation.

15. Use according to any one of claims 5 to 14, comprising in an amount of 10% by weight.

16. Avenanthramide L or NK1R antagonists or an oat extract containing avenanthramide L.

17. (a) Reacting triethyl phosphite (1) and methyl 4-bromocrotonate (2) to form methyl (2E)-4-(diethylphosphoryl)but-2-enoate (3). Step (b) In the HWE reaction, methyl (2E)-4-(diethylphosphoryl)but-2-enoate The methyl (2E,4E)-5-acetate (3) is reacted with 4-formylphenyl acetate (4) to give methyl (2E,4E)-5- forming (4-hydroxyphenyl)penta-2,4-dienoate (5); (c) Deprotection of avenalmic acid methyl ester (5) using sodium hydroxide solution. to produce avenalmic acid (Avn Ac); and (d) avenalmic acid (Av) was synthesized using a coupling reagent without the use of any protecting groups. n Ac) with 2-amino-5-hydroxybenzoic acid (6) to give avenanthramine. Step of generating Avn L A method for preparing avenalumic acid and / or avenanthramide L, comprising:

18. Preferably, step (b) is carried out at a temperature of from −78° C. to 0° C., in particular at a temperature of from −50° C. to 0° C. The method according to claim 17.

Citation Information

Patent Citations

  • An aqueous solution of a cyclodextrin-oatyl-o-aminobenzoic acid inclusion complex, its preparation method and application

    CN106491386B

  • A consumable product comprising malted dehulled oat

    WO2020065089A2